var title_f38_15_39152="Drug packet radiograph";
var content_f38_15_39152=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Plain abdominal radiography demonstrating drug packets",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In both radiographs, drug packets are clearly visible in the descending colon; on the left, they are also visible in the rectum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Traub, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_15_39152=[""].join("\n");
var outline_f38_15_39152=null;
var title_f38_15_39153="Fractionated photothermolysis";
var content_f38_15_39153=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F53757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F53757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 505px\">",
"   <div class=\"ttl\">",
"    Fractionated photothermolysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 485px; height: 382px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF+AeUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKCcUm6gBaKKKACik3UoOaACiignFABRSbqWgAoopN3NAC0UA5ooAKKDwKTdQAtFA5FFABRSE4oByaAFooooAKKTdSg5FABRRSE4oAWikByaWgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAKmoziCJGJxlwv6Gqq3ymSMZ+84H5ms7x7dG006zcHG66Vf/HW/wAK5i11Utf2K5+9cxL+bgVzzq8srHrYXAurRVT1PTaKKK6DyTIF+uW56Ej9av2Eomtw46ZI/WvNhqx3yjPSVx/48a7TwVcfadBSQnOZZB+TkVhTq8zserjME6FLn8/8zdqrqMwghVicZcCrVc547ufsukQOD1uUX+dazfLFs4cNT9rVjDuXlvlMka5+84X8zWrXmVtqpa/sVz965iX83Ar02opT57nRjsM8O436hWXLeqtxKmfutitSvNtU1Qx65qcefuT4/wDHRRVnyJCwOGeIlJLov1O+0+cTiQg52nH6VbrmPA119qgviTnbKB/46K6eqhLmjcwxNL2VVw7Edy/l28rn+FSf0rMF+u0HParGvyeVoWoSf3LeRvyU150mrk26nP8AB/Soq1OR2OzA4N4iDku56hbP5lvE4/iUH9Kkqh4ek87QdOk/v20bfmoq/Wqd1c8+pHlm49mUL+6EE6ITjcpNNtLtZblEB5INc343vja6xZID96B2/wDHhVbwvqJn8Q20Wc5jkP5AVi6vv8p6cMC3h/a+Tf5nfUUUVueSZC36kZzV+xlE1srjoSf5mvM4NXJj6/xH+ZrufBk/2nw7bynu8n6SMKwpVed2PVx2BeHp8772/M26oX90IJ40J+8pNX64rxvfG11iyQHG6Bz/AOPCtKkuWNzkwdD29VQ9TpbO7WW5CA9QTWhXCeFNQNxr8UWesTn8sV3dKnLmVx42h7Coo+QUUUVocgUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcP8WnKaLpxH/P8g/8ceuE0+YnV9KGf+X63/8ARi13Hxf/AOQHpv8A1/p/6A9ef6af+JzpX/X/AG//AKNWvNxD/e/cfa5RFPAp/wCI97ooor0j4o8F84iafn/lvL/6Ga9O+GDb/CURP/Pef/0Y1eUsf9IuP+u8v/oZr1T4Wf8AIoRf9fE//oxq83Cv958j7PPopYT/ALeX5M66uL+LDbPDtqR/z+xD9GrtK4j4u/8AIt2v/X9F/Jq7a/8ADZ85lWuMp+pwWnzE6vpQz1vrf/0Yte6V4Jpp/wCJzpX/AF/2/wD6NWve6wwmzPU4iVpU/n+gV4j4gmI8Va4Ael1/7Kte3V4X4kP/ABVmu/8AX1/7ItGM+FepPDivVqf4f1R3XwqcvaaqT/z8L/6Atd1XBfCT/jz1X/r4X/0Ba72tsP8Aw0efm6tjJ/L8kZPi448K6yR2s5v/AEA14tFOfsq8/wDLMfyr2jxh/wAinrX/AF5Tf+gGvD4j/oy/9cx/KuXFv3ke5w9FOhP1/Q9w8HnPhPRSe9lD/wCgCtesfwb/AMijon/XlD/6AK2K7ofCj5jFfx5+r/M8w+KchTxHpgB/5dZP/Qlqj4ClLeMbIE/8spf5CrPxZ/5GTTP+vWT/ANDWqHw9P/FZ2P8A1xm/kK8+T/f/ADX6H11GK/spP+5L9T2OiiivSPijwC2nPl9f4m/9CNer/DRt3g2zJ/56Tf8Ao568gtj+7/4E3/oRr134Yf8AIlWX/XSf/wBHPXm4R+/8v8j7TiGKWF/7eX5SOqrzD4pyFPEemAf8+sn/AKEten15X8Wf+Rj0z/r1k/8AQlrqxX8P7jxMhV8Yl5P8mRfD2Qv4ugBP/LvL/Na9ZryH4cf8jhB/17y/+y169SwnwFZ+rYlei/NhRRRXSeIFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHCfGD/kB6b/1/p/6A9ee6Wf+JzpP/X/b/wDoxa9B+MP/ACAtN/6/0/8AQHrzzSTnWtK/6/7f/wBGLXmYj+L9x9xk/wDuC/7ePf6KKK9M+HPntz/pNx/13l/9DNerfCv/AJE+H/rvP/6MavJpDi6uP+u8v/oZr1n4V/8AInw/9d5//RjV5uE/ifL/ACPtuIF/sf8A28vyZ11cR8Xf+Ratf+v2L+TV29cP8Xv+Ratf+v2L+TV2V/4cj5rKf99pep51pZ/4nWlf9f8Ab/8Ao1a99rwDST/xOtK/6/7f/wBGrXv9YYPZnq8SfHT9H+gV4T4mP/FWa5/19f8Asq17tXg/ig/8Vbrn/X1/7KtPGfCvUnhr+NU/w/qjuvhH/wAeWq/9fC/+gLXfVwHwi/48dV/6+F/9AWu/rbD/AMNHnZx/vk/l+SMjxh/yKetf9eU3/oBrwyI/6Ov/AFzH8q9z8Yf8inrX/XlN/wCgGvCoj+4X/rmP5Vy4z4ke9w2v3E/X9D3Twb/yKOif9eUP/oArYrH8G/8AIo6J/wBeUP8A6AK2K7afwo+VxX8efq/zPKvi1/yMemf9esn/AKGtUPh2c+M7L/rjN/IVe+Ln/IxaZ/16yf8Aoa1n/Dk/8VnZf9cZf5CvPl/vHzX6H2NFf8JK/wAEv1PZqKKK9M+HPnaA/J/wJv8A0I16/wDDD/kSrL/rpP8A+jnrx2E8f8Cb/wBCNexfC/8A5Emx/wCuk/8A6OevNwf8T5f5H23Ea/2Vf4l+Ujqq8q+LX/Ix6Z/16yf+hrXqteU/Fz/kYtM/69ZP/Qlrpxf8N/I8PIP99Xo/yZV+Gxz4wg/69pf5rXsFePfDQ58Xwf8AXtL/ADWvYaWE+D5l8Q/70vRfmworJ8ReJNF8NW8U/iDVLPToZW2RvcyhAzYzgE98Vo2dzBe2kF1aSpNbTossUiHKurDIYHuCDmuo8IlorMt9e0u41240a3voZdTt0Ek1uhy0YOMbuwOGBwecEGtOgAooooAKKzrPXNMvdKn1K1vIpbGAyrJMp+VTGSHz9Cpz9Kn0u/tdV062v9OnS4s7mMSwyp0dSMgigC1RRRQAUVS1rVbHRNLuNR1a5jtbG3XdLNIflQZxk/iRVuN1kjV0IKsAQR3FADqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDgvjF/yAdO/6/wBP/QHrzvRznW9K/wCv+3/9GLXonxj/AOQDp3/X+n/oD15zop/4nelf9f8Ab/8Aoxa8vE/xfuPusm/5F/8A4EfQdFFFeofCnztKf9LuP+u8v/oZr1v4Vf8AInQ/9d5//RjV5FOf9MuP+viX/wBDNeufCn/kTof+u8//AKMavMwn8T5f5H3HEK/2Jf4l+TOvrh/i/wD8iza/9fsX8mruK4b4wf8AIsW3/X7F/Jq7cR/DkfMZR/vtL1PN9HOdb0r/AK/7f/0YtfQNfPein/ieaV/1/wBv/wCjFr6ErDBbM9bib46fo/0CvBPFRx4t1z/r7P8A6Cte914H4sOPFuuf9fR/9BWjG/CvUnhn+NU/w/qjvfhD/wAeGq/9fC/+gLXf15/8H/8Ajw1X/r4X/wBAWvQK2w/8NHm5z/vtT5fkjI8Yf8inrX/XlN/6Aa8HiP7lf9wfyr3jxh/yKetf9eU3/oBrwSI/ul/3B/KuXGfGj6Dhr+BP1/Q968G/8ijon/XlD/6AK2Kx/Bv/ACKOif8AXlD/AOgCtiu6n8KPk8V/Hn6v8zyj4vf8jDpn/XrJ/wChLWf8Nz/xWVl/1xl/kKv/ABg/5GHTP+vWT/0Nazvhqc+MrL/rjN/IV50v94+a/Q+zo/8AIo/7cl+p7TRRRXqHwp84xH/0Jv8A0I17J8L/APkSbH/rpP8A+jnrxiM8/wDA2/8AQjXs3wu/5Eix/wB+f/0c9eZg/wCJ8v8AI+44k/3Rf4l+Ujq68o+L3/Iw6Z/16yf+hrXq9eT/ABg/5GHTP+vWT/0Na6sX/DfyPC4f/wB9j6P8mcr8PvC1nd+KokkvdaQNBK2YtVuYz1XoVcED2r1b/hA9O/6Cnib/AMH95/8AHa4f4XnPi+D/AK9pf5rXslLCNuGo+IIRhikoq2i/Nnnfxt0nWNX8BjSfDulT6ncyXNsxC3ESbFilSQlmldc5CY4ycn8a4T4jeBfFniPU/FesWFhfxXj2+mS6NGNSWPyp1ceeNok2blXcMng87Sc17/RXUeGeCeIvhrrj3PjO50exuYrnU9dtLiCWG/8ALZ7X920zD94NvzB/RuMDjFQ/EfwJ4judekh8L6NOkFhFaNpl8l2XlcrKGlDyyzgpgE4wrFs8mvoGigDw3VvAXiy50n4j3Vg95b67fX8n9jsdSYIbVjEXCqH2IzBXUFgGHqBWCvgXxJDZ2yxaXrNzoJ1WC5v9F3xWxdBGyt5Y+0vld2wsGcAnkdMj6QooA8z8BeGNU0r4Q6pol1YG1v5zqHk2rTI5AlkkMYLBivIZe/1ryzxJ4A8d3HhvRLDTtCeHU9M0Syitru3ukEi3COPMRnMyqm0E4Kq27+9wMfT9FAHg9x4S8YD4q6pqemWs0kVy1yY77UXVfsWYWSIwskxLpuIOxohjnPODXOaZ8O/GsXhvVYIotZi1W5sIILiPzoo4p7hLqF2lEv2hmZygl+bCZHHBOK+m6KAPPPiX4PmuPg7rfhnwtbTXFxNCRbxTXTSO7NKHbMkrEnksfmb29K801DwF4v8A7P1yPw7Yahp+kT6hp8r6Zc3olmuY40cXJX99jDsYztMi7th5HFfR1FAHzjq/gfxVN4W0/SLbSLy7tPOvnjkuTGs1lvRTEiJ9p2qm8NhmZ2UDoM8xeIPhz441jSla6tr+XUbbwtZ29uRqaoRqUc2WJxIAWCZ+c5B9c19J0UAfPviD4eeIYrXxJZadHrEem3V9YXcAguFuvNKwN5/mJJOrMjSbdw3Ak4IBANer/C2y1LTvAelWmt2EGn38av5ltC5dUy7EdWbBIIJAYgE4HAFdXRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBwXxk/wCQBp3/AF/p/wCgPXm2hn/ieaT/ANf9v/6MWvSPjL/yL+n/APX8n/oD15roR/4nuk/9f9v/AOjFry8T/G+4+7yVf8J3/gR9EUUUV6h8IfONyf8ATbj/AK+Jf/QzXr/wp/5E2D/rvP8A+jGrx66P+nXH/XxL/wChmvYfhR/yJkH/AF3m/wDRjV5mE/ifL/I+54i/3Jf4l+TOvrhvjD/yK9t/1+xfyau5rhfjF/yK9v8A9fsX8mrtxH8OR8vlH++0vU8z0M/8T3Sv+v63/wDRi19DV876Cc69pP8A1/W//oxa+iK58Fsz2OJ/4lP0f6BXgPi4/wDFXa3/ANfR/wDQVr36vn7xgceLtb/6+j/6CtPG/CvUjhf+PU/w/qj0D4Pf8g/Vf+vhf/QFr0GvPfg5/wAg7VP+vlf/AEBa9CrbDfw0ebnP++1Pl+SMjxh/yKetf9eU3/oBrwGI/u1/3B/KvfvGH/Ip61/15Tf+gGvn+M/Iv+5/SuTG/Ej6Dhj+BP1/Q9/8G/8AIo6J/wBeUP8A6AK2Kx/Bv/IoaJ/15Q/+gCtiu+n8KPksV/Hn6v8AM8m+MX/IwaZ/16yf+hLWd8M/+Rys/wDrjL/IVofGT/kP6Z/16yf+hLWb8Mf+Rzs/+uMv8hXnS/3j5r9D7Sh/yJ/+3Jfqe2UUUV6h8IfNi/e/4G3/AKEa9o+F3/IkWP8Avzf+jnrxRTiT/gbf+hGva/hb/wAiPYf783/o568vBfxPl/kfdcSr/ZF/iX5SOrryb4xf8jBpn/XrJ/6Etes15L8Y+Nf0z/r1k/8AQlrrxf8ACfyPA4e/36Po/wAmU/haf+Kvh/69pf5rXs1eL/Cs58Xw/wDXtL/Na9opYP8AhmnEf+9r0X5sKKKK6jwAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoopjyon32A+poAfRTEljf7jq30NLJIka7pHVV9WOKV0Ow6iqUmq2MbbWuoyf9k7v5VH/AG1YdPtAz6bT/hUOrBbyRSpzeyZo0Vjv4isEcrmQn/dp667ZsM5cD3A/xqPrNL+ZF/V6n8pyvxm/5F7T/wDr+T/0B6800A/8T7Sf+v8At/8A0Ytd78XdVtbnQLFYmJK3yE8f7D15vod7FHremOxYhb2Bjgeki152IqQdW6Z9zktOSy6zX8x9K0VhnxHb/wAMEpH1X/GkHiOHPMEmPqK9D61R/mPh/q1X+U8Juz/p9x/18S/+hmvY/hR/yJkH/Xeb/wBGNXidxdxSX9xhsEzyHB/3zXrvwx1aytfBsImmAYTTEgAn/lo1cGEqRVS7fQ+24ihJ4JJL7S/Jnf1wvxj/AORWt/8Ar9i/k1dDH4jsXbC+bt/vbeK5H4t6naXHhiBYpgW+2RnGCOzV2Vq1OVOSUkfMZTSnHG0m11PO9AP/ABP9K/6/rf8A9GLX0XXzdoE8Y17Si0igC+tznP8A00Wvod9QtFGTcRfg2f5VlgpxSd2etxRBupTsujLVfPvjI/8AFX63/wBfR/8AQVr3Btc05W2tcqD7qR/SvBfGN7bv4r1l1mUo11kH/gK0YypCUVZ9SeF4SjXqXX2f1R6V8G/+Qbqn/Xyv/oC16FXlvwi1ixt9O1JZZwC1wpGFJ/gHoK7469Y9pCfoK1oVqcaaTkjzc4pTljajSfT8kM8Yf8inrX/XlN/6Aa+fIj8q/wC5/SvbvFeu2EnhjWIxLhms5gM+uw14Sl3AFUmVcbPX2rlxdSEpJxZ9BwzTlGhU5l1/Q+ivBv8AyKGif9eUP/oArYrkvCmv6dB4T0ZWn3MtnCCFUkg7BWmPElgRwZv+/ZFdsK9NRV5I+TxNGo607Re7/M8++Mv/ACHtM/69ZP8A0JazPhcc+MrP/rjL/IVL8WtStrvWtNeJyALaQHcMfxCqPw0vLeDxfaPLKqqIZec+wrglUi6/NfS6Ps6MJLJ7W15Zfqe70Vnf21Yf89x+RoGt6d0N3GD78V6Xtqf8y+8+E9lU/lf3Hzxn95/wNv8A0I17b8LP+RHsP9+b/wBHPXhf2mEyZEqffb+L/aNeyfDbV7K28E2CSzfPvm4Ck/8ALV/avNwk4xm230/yPueJYSlhIpL7S/KR3deSfGX/AJD2mf8AXrJ/6Etd/J4ltUPFvduPVUGP1NeXfFnVre71rTXVZYwLaQfOuP4h6ZroxNenKm0meFw/RnHGxbXR/kyT4UnPi+H/AK9pf5rXtNeG/Cm8gHi2I7+Ps8o6H1WvbUuI3+6T+VXg5L2drj4ki/ra9F+bJaKAc0V2HzwUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVn6kW525/LNaFUNRUHOSfzrOr8JdP4jlr1rgOSIt3vjB/MVns6li0iDf6yS5P5VpajHHu5Iz/ALbqP6VnNJt4S5hUDsJF/wDia8OtuezS2EV7hv8AVxlR7DaD+eDTjHdP97Cj3JP9aQsWH/Hy7f8AXJSf1HFRtDLK2P8ASWA/56FQPyFYGpIgSPOXQN6KFz+WKa8iKehHuYv8KkS1mTGyZl/2dwx/Knqlyp5YkezA/wAwKBnG/EkhtEtDuRh9qXkhh/C3rmuG0bB1jTwNuftcPTk/fHpXe/E6RhotoHJU/a1+8v8Ast3FcLou59X08BwAbuHlR/tiolufXZWr4L7z2dl+XLhyPUqv9ahGw55kP+6it/IGptkQb/XszD2DH+Rp27/bmP1j/wDrVZ8geGXIzeTAZx5z9Rj+I16Z8P4F/wCEYhZ+QJZfvEAD5z7V5neuPtk+7H+ufqCP4jXpvw7MjeGYfLiUDzZfmI5++aiO59ZnS/2Veq/JnQvLEeDIOP7srH+Vcr8SWz4fhO5iPtKfeJPY+tdkon7lD+Nch8TAy6BETFg/aU5VvY1T2PAy7/eqfqee6Oy/2vp+SV/0qHnj++K9o8kPw8kjL9V/xrxjRTnWdP4jP+lw/e/3xXtgRSeI7fPsf/rUonp598cPRjUjSM/JgH1yuf5V5B4oLf8ACR6phif3/qP7o9q9kKS8bVhA9wa8Y8Uxt/wkmqbgv+v7H/ZHtRMWQfxp+n6o6/4bsy6ffl3jQecMlpCP4R6Yrq28tzkhXPs2P1I/rXLfDLbHY3xIhU+cOWbn7ors2uGUZxu/3UY/yFNbHBmn+9T/AK6IydeWMaBqYAx/osnSfP8ACe2a8hQYK7VbO3qNvpXsHiS6kbw9qYNu5BtpOSCP4T6ivGo3U4yir8vdvapmezkP8Kfr+h7P4cEzeHNKC+YP9Fi7r/cHsavNHIPvyMvuWH+Aqh4Z8o+HNL3Pbj/RYuOM/cHvWitrGw/cyBT6pj+lWj5zEfxZer/M83+JagarY/vQ37h+c/7Q96peAF/4qW3Ch2/dydD7CtD4mq8Wq2Ie43/uH+9gY+YVR8AN/wAVLb5Uv+7k6EnsPQVHU+opL/hM/wC3X+p6gy7TgrCp9Gcg/wA6UbgPvp/31/8AXFSxvKOEtgq+u7H6YqXdL/zzT/vs/wCFWfIngTOfMOXP3j0HufevUvAGB4XtCkTFi0nOQP8Alo3+eteXyE+cf3IJ3HnI9TXqfgJXPhS0/dEDdL91V/56N6mojufW56rYZf4l+TOiVHxnygD7Kuf51518Tsrq1jkKp8h+q4/iHcV6F5cQ5dpoj642j8wMVwHxOwNVsD5xIMD4JI/vCqlsePkv+9x9H+RH8L1LeKIvljb9xJ791r3SyUAD5QPyrwr4XmNvFEeWDfuJOwPda92sQAo28fjXo4HY4+Jv95XovzZop0p1InSlr1kfKhRRRTAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqhqIHOWUfUVfqhqE0MQJl8zgdEGTUzi5KyLg7M5u8SNmOXZvYJ/wDWqjhVPyeaPpGB/SruoavZxMR9kuZDnGTIF/GsSTxBBwRp0i5/ha55/lXBPLa83dWPUpVbLZl0sT/Hcj/gH/1qZJNt6Ndn6Rf4iqy+IrcsVbS5gAOGF11/8dpy+IbEKplsbpc9QLhTg+nQVn/ZOI8vvNfbeT/D/Md50+ciVgvo0RJ/QD+dSrN3Z5/++AP6UxfEWlHbusNQBbt5gOPrR/wkGlyFMQajHuzwQhxj1pPK8QuglWXZnLfE6UHRLQCQn/Sl4ZP9lq4DRQp1rTxtQk3UP/LP/bFdz8TtX06XRLIQvd7jdrxJEBjCt6GuB0HU7T+2bBmeUIt1CWPl9BvHv1rjqYSrCfK1qfYZVWh9Rd33PbUiXJ/dSrj+4ir/AC5qZQFGN1yMeoz/AI1XfXNHPW5v1wMsFhQY+uTxTf7Z0EECSTUDxubeiEL9cniur+zcR/KfIe2j2Z4teSAXs48wn98/VefvGvT/AIeYPheDLTH97LwqY/jPfH9a8ovNSsvts2GuAvmucFVGBuPWvUvh1rejx+F7VJ21DzWllwsaoeN5557Vz0cHVqS5Yo+tzuvH6pG2uq/JnTyZC/LBOx9S/T9a5P4jhh4fiLTkD7SnylcY6+vNdV/wkOg4BB1J8nC7RGd/rjnnFcl8T9c0ifw9GtsL0n7UmC+za3DZAwetb1Mtrxi5NHz2W119ap6Pc4XRNp1nT/vN/pcPY/3xXtbqf4YV/wCBJXhehanYx65p25bjYLuEtjHA3jP0r24+ItFJAjg1Ektjt09evT3rOhgK1VNxR6nEFePtIWXRi4kGf3IAP9xD/iK8b8UJ/wAVHqfBX9/0KZ/hHua9jXxBpDrlReAH7vyKd30+avF/FupWj+JdVZHuChn4+Uf3R79aK+BrUknJE8P1oe2nft+qO7+GDFdOv8MV/fDpEf7orshOp6XEh+kf/wBauD+GOqaPFp9/9ra7LeeNu1EOflHAyevtXcf8JBoKg5l1IBevyx8H+79faqp5fXnFSSODNK8frc9P6sip4kZv+Ee1PDyH/RpOseP4T7CvFw7jbgMfl/u+1eyeJdd0RtA1OON9R802kpwyx4X5Djd6V4mup2YK5Nx930Xpjr9Kzr4KrTaUke1w/Xj7Kd9Nf0Pb/DDt/wAI5pYkmjUG1iAAXB+4PU/0rRMcLH5kkkPupH+ArI8N69og8N6VFNHftJ9liBX93g/IMsOelaaeINCCgJDqLKfuncpDew5rojlldpOx81Xrr2stHu/zPPfidGiapY7LcJ+4fsP7w96o/D5QfE1v+5z+7k6Y9BU/xS1rTZ9VsWt4btAtu4cSMMqcj0NUPh5q9lF4mgeW1uZAIpPkVwCenfOP1rmeCqqrydT6ujXj/Zfnyv8AU9bJkPS3kA/664/kaQNKPuyBfaQn+oB/Woz4m0bAI0+8KZxu844B9OtIfEmllhH/AGVd5PJBuDwPXriuz+ya/kfHe3/uv8P8zxN/M80/dzuP8zXqfgFZj4TsyWXbul6Nt/5aN7V462p24m+W2lAZ2wN56ZNer+Atf02PwnaJcabcS7Gky6zNgnzG4wPr6VyUMDVqy5Yn1+fYiLwsba+8vyZ1J2k/6hZT6hi36kV558TAF1Ow2weX+4fjj+8PSu/XxJphyP7IvNwxkfaD+hzg15x8UNasbjVbBoLK5iQQOvzOTk7h681tWy2tThzSseNkldfW43TWj/Is/C0v/wAJTHtUf6iTv7rXulnnA3A14H8KNRtR4pjL285HkSZAbpyvv/KvfLK5glUGOORR7mujA0JRjdnPxNUUsVp2X6mglOpEII4pa9E+XCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsjWsnOPStesjWeremKqO5cNzh9WUlxh2AHYY5+tYcyqzbTjcOR6j3rc1Qfe2YGeeRWLL15ruhselT2I8DK5JyPfrUaIFdvLjVQTljjGfepO/QY9aMfMTk/SrLGuMA5YBSed3T6U1kVXMhbaoXB5xgetSDkDdg0KSR8wwe4oA5P4iD/AIlVu4O4faFwAB/dbvXF6OudXsc9PtEWVwOfnFdv8Rf+QPbf9fK/+gtXDaM23WLLhj/pER/8fHFeLjP94+4+py3/AHN/M9eOHQOVYDqVwMn2IokKmIOWdAME4HOPSlDAhZGLIMZKnH604bi+cjZjgY7/AFr2j5Y8bvM/bZvTzX/9CNeheCP3fhuNhn/WSE8Fv4j0FeeXu37fN03eY+PX7xr0TwPuPhqABlVvMcnvxvNeNgP4z9P8j6jOP91XqvyZ0AKhgd2C/QE/yFc18QVxoynLczp3479q6UNvKMmxk5+bP8q5n4h86NEpTIE6HdxgHmvSxX8GXoeFgP8AeYepw+j/APIVsARuzcxA/wDfY6165t8s7gGfJwAAPlH6cV5Fo/zavZL8w/0mLkf74r2DcN4XBzjOccfnXJlvwyPSzz44eg1lKBmBJGMhMDj6V5R4n/5D+oNg/wCu6fgK9YP7tDwzY/E15P4nIHiHUTkn99jH4CnmXwL1JyP+LL0/VHVfD7As7li7D9+BgdCSo611+D824gr2AHIrj/h42LC9VSoYzDaWOcnaO1dYCHJeNVLhcK5HBz6H0rpwn8GJw5j/ALzP+uhR1oEaBe7MhPs0md+S33T615PHjdjnp3+leta/g6LqHJ3LbyEgdPumvJVJ3c4xj19q4My+OJ7GR/w5+p6z4cBGh2Iw2Ps8ZyTkH5R09Kvg7o1B+cNwWXgfXrVDQG/4p6x2naVtoxlwcfcHPuKvdVVFJUEZ3IBjt/OvUp/AvQ+frfxJerOF+Ig26jYqDwIGHJyeoqj4Fz/wkFuFIxsfOee1WviK4bUbNk2jMLBWJzuGRVPwMf8AifRGPbko5549K8if+9/NfofSUv8AkW/9uv8AU9NC/OWy2SMYzx+VN2mRRvDJhsgBuuPp/KnEIJAxwGPyg/0pN+1cylF5wOfy/GvaPljxiTDueoBY+x616X4KO7wva7SV+aTkj/po3rXmchxM2TnLnH516X4KBbwxAHVWUmTC+o3t1rxsu/iv0/yPqM6/3ePqvyZuSAM6Bo94B3BuPlNcJ8Rv+QnYsAT+5YcH/aFdtLJ5YjGNnyk7NuQcDpntXB+Pi5vrExwkRiFgu0cAZGenoeK7cf8AwX8jyco/3qPz/I0PhZj/AISiMnHEMnJ/4DX0HpX3F3YzXzv8Kmz4nAIH+ok+90z8tfRGlHKDFcmF/hfMx4h/3n5L9Tcj6U6mx9KdWh82FFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFY2tnJKjuK2aqXYG4nHNNO2pcNzzvVCDnnGPesKRlkLYGdrfxDHP416Bq1lBdgiVBuxw3cVwd3GbW4MEgO5Tt3EYzxx9fwrqoVVPTqelBWRCQcMAxyeh9KCNy4OR+PNNjYFmIfI6EcfKat2FjNfPuRCseMF2GMe1bykoq7L3K/PPYYpe1bY8PLswbhmbbjJHB/CqE2lXcLD90ZB0zHyPyrKOIpy2Y3Fo4n4i/wDIHtv+vlf/AEFq4TRhnWbA4PFzH/6GK9B+Idncf2RbFoHQ/aVHzjA+61cv4asIv7b05ZAXJu4c8n++K8fHVYxxH3H1uVUZTwTa8z0QSKzFGHJJGD3/AM81LEW2/OACD29O1aHiXR47aMXNmjKp+WSNMc5PXn8e/es6EkxA/KPTacjHavbp1FUjzI+RtY8avmIvLjoP3j4PXnce1d/4JuETw/GQgLbn+Y8fxMefbj3rzu7DyX0iAc+c3TPXcf617t8K7O3tvCduyxoZmeQM+BuIDt+leHhqypVW32Pqc2i5YVPpdfkzMS5SQmN+A2F2kdCR3IP4fWue8fNnw9bjjBnTlDkDAPevV9T0m0vsNIvlyr92ROCOc8+vSvLPiZpt5p2ios4aS385QJFPy8k456g4/wAmvRq4iNSjJbOx4eBVsTD1OE0bLavZDkZuIgCDz94V7CuQNuDxwCT1rxnRJAdZsOgk8+LnGcfOPxr10zxgN5eVG/LEEc+/4kY9azy34ZHoZ47zh6EnSJwvyyD5mEeOvXv615Vr8DXniPUfLIEZl5bGR90Yr1mws5tXn2IhEKvhnI+6Mcg+/PSuE8UQJa+IdShjyQs2Cx6n5RyazzaqowUVvcvh2l7SvJPa36o6j4Y6DZ3Wk33mGXeJxhgf9lT0Ix1FXr2CXT76S1mZmOAVdW7Z4IBJ9/yxzVn4T86TfgdfPH/oAroPEGmf2nbCSID7TDnCkD5h3H88fWpwGIcYpTehx5vBLF1Lf1ojjNcO7RdTIYkC3cYxjnafz615Gp5Dbedv49K9T8QmaHQ9RinjkV1hf7wK8/N79OOK8nDFpRsjZiq9hzRmT96J6OR/w5+p65ojlPD9gNzH/R4zng7flHGKvXEcdrZx3mpB/wB98sECKPMds+44UHGDjPPfipvBmhyT6Npst8GSEQRsOcFwVBA47dua0dTCN480hbgDy1gZo1PQN83+A/IV0VcTywUYPXQ8V0+atLm8zy34jKy6jYLdWcljI0LeXufdu+YdfTk//WrP8CHOuxCQgKI5C+8ZGMDPpiuo/aBVZfsbofmjiLA+nzgfyNc14Ht5f7btbmKPcjwtL8ucAYHXH1NefTlzV1Jvr/ke9C6wLjb7N/vbX6Hpu/8AeMNw2quSNp/n0o3jaZd4MW3I4/Wq7TsrASA5QE4XOSegyBnAOcjvTmn2uGPXbgjcSNw5wBjk9enpX0B8seOyEmZjkYLHH5mvSvBbKnhu0cpl/wB4DjGQPMavLppP3sh5zk57gc81638OdGuNQ8P2RdPKtcSDeyjlS7cDnqCM+leJgZKFRuXb/I+oznXDxt3X5M6Hwzpq6g7z3Q3wxnZsJ3BjjkHPpn0HpWF8WRt1TTgoAAt3AH/AhXpNtEltCkEI4UY56/U+9ebfFv8A5Cmn/wDXB/8A0IVlmFV1It9DjyFWxkfR/kZ3wys0uvFC4AWUQOQ2Pda9x0gMq7WyCOPpXi/wlP8AxVaEf88JP5rXukUYDiRcYPWnl837KzOfipJYvTsv1NKPpTqZH0p9dh8mFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFVbvqatVQ1CZIs7jz6Ck1cuG5l3Qyay7q1iuMedEj46EjpSX97eO37iFI09ZDz+VY8mq6lb8zWySqBk7eKhQd9Gr+p6tN6F8aTZBw32dS3QE5NXVQIoVVAUdAB0qjpusW1+5iTck6gEow459D0NaNRU507TNU10GHpSASYzhfzqTPtSZ9MCoKucT8VQ39gWu5f8Al7XkH/ZavOfDh/4n+m/9fcP/AKGK9H+Km7+wLbLA/wClr/6C1eb+HMHX9NB/5+4f/QxXm4j+Kj7XJ/8AkXv5nvkipIjI4VlI5B5zWPP4dtWXZAzwJ/dXBHXpg1sbQv3QooAYjhh+VerCpKHws+IaTPnS5s4rXUJxGpLCaQb26/eNew/DUhfCdvgZYyS/+hmvJ9XyNTuQevnyf+hmvWfhsdvhK3x/z0l7f7Zry8M26rbPtM8io4GKS6r8mdRl+5UH0rjviiG/4RqPPT7TH9O9dh5gPDIfyrkPifj/AIRpdpIH2mPg/jXXW/hs+cyzTF0/VHluhWlvLrunrJBGwN1ECMdcuM5r3aPSLCPlbOLPvzn868P8O5PiDTsH/l7h/wDQxXvRz/E4rLBTkouzPV4kglVhbswiiWKNY4lSKNRgKgwBXiPjXC+KNV2/89//AGUV7eEDdW49BXiHjhdnijVAMAeeP/QBSxnwp+ZPDf8AvE15fqjtvhMD/ZV+ep88f+gCu5IVjkHa1cP8Jd39k32CP9eP/QBXcsCfvID7itcP/DR5+bf75U9f0RneJAx8O6oGII+yy/8AoBrwccOo/wBn+le7eIkB0DUgqsP9Gl6/7prwfOJAMdv6VzYz4ke7w3/Cqep7x4XH/FN6SRj/AI9IuT/uCsrxvE1oNP1iFS8tlMN+O6N1H9P+BVqeFyD4a0oHb/x6Rd/9gVfurWG8tZbeZcxyqUbtwRXbFXij5irLlryb7s8j+OlxFcWljNCwaOW3JRh0ILriuU+G9xPHqVm9zqS6fAkDKu1SzEAAdBzzS/EiS4s4l0i5JeS0ZwjY/hLKc/1/4F7Vq/Bi0tZNasnaJZGEUmSwzggAcelc/O4zulrf/I92NFSwrTeig9na+r/zOul1iJP3iav53OQt7ZOFcj0Yg/0+tdZoa2mp6ZHdmwgiaQFWAiGDgn9DyfxrckjRkKsm5T1HUU1ViVAoG1QMAdMV6Mq7lGz377fkfKxpKMrxvbtufO80McVy3lxouHI4UDjJr2P4eN/xSFlufAzLwP8Aro1eQXwC3kgyeJG/9CNewfDpCfCNiVCjmTk8/wDLRq8fC61H6H3OfpLBx/xL8mdKm5h8vyr6nqa8z+LIxqen5Yk+RJ1+or03a+OWrzP4tA/b9OJ7wSfzWunFfw2eFkb/ANtj8/yZX+Emf+ErXb/z7yfzWverT7vIxXgfwiP/ABVa4z/x7ydPqte+WpOBWmB/hnPxX/vfyX6lxadSLS13nyIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVnamE5LAfjWjWTrOQCQpYDnHrRa+hcNzmL+8WO4wxGzn5vT61FIA6kjhh1HrVm7ih1C3kSNVimXkEVjR3EluwiuQVdeCW7+/vXPXw99Ybo9Wk9DNvB9jv4biFcbHzt5AIx0x9a6rT7xL23EsfGeGHofSuc1PymTcS2FGd2eKueEI/+JdJjKr5hwNu3/P1710StOgpPdFrc3SGz98Y+lHTupPvSGNB16/WkEY7NXIa6HI/FHJ8ORE44uUP6NXmPhs58Qadx/y9w/8AoYr1L4mR/wDFMMSxOJkP615d4UwfEmnA9PtUR/8AHhXnYn+Kj7PJX/wnz+f5Hvvy54ODRz2b+VNJjPXApQiHoRXonxh4Dr4K61eDI4uJP/QzXq3w2fb4St8sB+8l/wDQzXlXihdviC+Uf8/En/oVesfDiNh4RsyMctIf/IjV52F/is+yzxr6hTfmvyZ024OMYOPWuT+JisPC7Z5AmjP611TBx/CD+Ncv8RnLeFpwykYdD/48K7a3wM+Zy7TFU7d1+Z5X4aOfEOm/9fcP/oYr6A3L3I/OvAPCeH8S6aMf8vUR/wDHxXvxCd8Vz4L4WezxP/GgvIaTFnqteJfEDA8U6jt6GRT/AOOLXt2Ih/drxT4kbR4ovNvQlT/44KeM+Beplw2/9qkv7v6o7D4SbjpN9tP/AC3Hb/YFd4PM9R+VcN8If+QJeH1uP/ZFruD5hPGAK1w/8NHn5v8A77U9f0KetfNo9+pYcwSDH/ATXz+T++H0/pX0BqayfYLoFFYGJhx9K+e2IFwOO39K5sbuj3uGV7lReh794YDL4b0rAX/j0i/9AFaRY91GPrWfoAH9gaavzcW0Y/8AHRV4Q55ya7Y/Cj5avZ1ZN92eNfG62jh17TLry1CzQsr++0gHP4EflWN8G3+xeOhYysQrJJ5ZJ6nAx+Y/UV1Xx2tw1jp7jkxlyfocA/4/hXH+DLeS7vor23B+0W0DOzL1wCuT+B5/OueFniOR7Ox7/LJ5V7WG8U/mtU0fQ5G0feNJluyk/Ws7RNWTUbCObbiT7sij+Fh1/wAavmcdgTXXJOLsz5mL5kpLqfPusZXVbgYxiZ//AEI1698PGP8AwiFiDuHMnT/ro1eR+ISf7cu+Mfv3/wDQjXsXw/Qr4R07LcYc4/4G1ebhf4jPs8/f+xU/VfkzcYEg4aQV5v8AFpHWbTSxz+7lH/oNenMMjg4Nea/FwOq2BJzxIP5V1Ylfu2eJkcv9th8/yZQ+D7f8VWuQf9RJ/Na99tTkcV83fCjRLC98UMs8czDyJGO24kXnK+jD1r3C28H6MQMw3X/gdP8A/F1eBt7PQ5eKub637y6L9fIt/ELxOvgzwZqWvvaPeLZKjeQj7C+51XAODj73pXGQ/GrSr3XNL03S7Nrhr3SJNUaZptiQFY2k8l/lPzfLz6ZHBrsPGfhOHxN4Iu/Da3L2kE6RoJcGVkCOrDqcn7uOTXP3/wAJNCOsQX+jBdLwuomeOJC4mku41RnyW+XbtyFHHpiu8+TL1l8TvD50/R5NTu0t73UbSO8FvbJLdLHG/AZnSP5UzxuYKKtN8SvCCnUgdcgzpxZboBHJjZZBGVxt5beQAoyTkYBrA0P4Zah4buLKbw34lFm66dbabeedYLN56wZ2umXHlthiP4h7VbufhlDL4SvtGTVJUmm1h9aguvJB8iYzeaoKZwyg8EZGR6UAM1X4w+FrL+x3huJrqDULySydkglV7Z403N5kZXeCMqNpAPzZxgGl8MfFnQ9W8S6joF+w07VYNXuNLtoWLyC58rHz79gVC2ThCc8dTWb/AMKmvEZdSi8SKPEh1j+2JL1rAGFn8oxeWIfMGFCnrvJz61ch+FMMV+lz/ashK+J5fEu3yB9502+T97oOu79KANy2+JXhK5u7y3h1hDJawzXEjGGRUaOLPmNG5XbIFwc7C3Sqlx8WvA8Fkl2+vRtbyeZsaOCWTfsVGfAVSTgSITj19jjmdK+C0enWtxYR6taPp32S7s7Utpim6hSdGTBn3/MFDdlUnAya6W++HkV3/YWdRdf7L0e40gfugfMEsaJvPPBGzOPfrQBb074l+EtSS9bT9XW5FnbpdSiKCVj5THAZAFy4zx8ucHg81nal8U9HFrpFxoYOpLea7b6HOjh7aS1eXPzMjpuyAPukDOetZM/wgb+x4rSx8SXllcRaBFoSXMMW1gEmEvmcMD82NpXPQnmo9L+DUNl5bPrALjXrXXWENmIk3wKR5arvOFbOc5JHv1oA7vxZ4y0LwjHFJ4hvjZxyAsrmCR1wMA5KqQOo64qjcfEfwnb6nbafNq6Jc3AhK5hk2KZRmMO+3bGzDkKxBPpVf4j+CrzxjJpax60tlZWUpnezksxcRXMg+4ZAWGQvUKeM8noKwtb+E82r3t79o8QsNM1S4tbzVLVbNd9xNAFGY5N37tW2KSuGx2IoA6S0+JPhK78QpodvrMbam8ssCxGKRVMkWd6byu3cMHjP0qK1+KXgy6F40WuQiO0ga6kkkikjRolbaXjZlAkXcQMoW5NY7fCe1kawE2pyvFbaveaqyiEDzPtO4NHnPGN/X26Vk6T8F203SptNXV9NuLUWrWlu9xosckyxl1bErF8OMLjACdjnIFAHpfhvxFpviS1kudJkneKN9jefay27A4B+7IqnGCOcYrXrjvhj4LfwTpN5Zyam98Li4M6qqNHDANoGyNGdyq8Z+8eTXY0AFFFFABRRRQAUUUUAFFFFABRRRQAVS1DofpV2qOodG9RUT2Lp/EcVqkM8E7SWkgTdkHPP/wCrtWFcXN9AxN24ntwMsrDcW+npXWX459axbyLzEfCqT6E47UoYqzSkj1Ka0H22madexQzpvKt86jecdMVrxwxxRLHGu1F6AVxUkz6dcNLBIVjBAkBztVQM9/r1FdrbsGgR1JIZQwJ96qupWTvdM1VgMQJzk5pph9GOalz7ijntiuYtSZyXxIUr4Vm3HI8xMfnXl3goBvFWnKRn9+p/LmvU/iWW/wCESuSw6PGf/HhXl/w/G/xlpwHOJCfyUmvPxH8aPyPscmf/AAm1X/i/I958tD2pvkgcqSDSuzdlpp809sV6B8er9zwLxYSviG/z2nf/ANCr1/4fgjwhp4A6hj+bk1474wyviTUVJ5Fw/wD6FXsngZXj8J6b6GPP5k15+F/iyPsM9/3Cl6r8mdCN3cg1zPxGwfCd1nsyf+hCulVgw965r4jA/wDCI3p9Nh/8fFdtX4H6HzGA/wB6p/4l+Z5R4KXd4s01c/8ALZT+XNe9nA4JzXgfgL954w04Zx85P5A170gQDrmubBfAz3OJ/wDeIL+7+rDKf3f0rxX4mBR4nusf7P8A6DXtxPHAzXiHxTyniu44xuRD/wCO08Z/D+Zlw1ri2vJ/mjs/hJGT4cnZTgm4P/oK13Sl+4BriPhOkg8K5Xo0zH9AP6V2gjf+9W1D+HE8/NtcZU16jNQ3GyuMcfu2/lXzjMxE4r6NuS3kSoe6EfpXzdI2ZwO+cVy477J73Cy0q/L9T6L0qTZpdouw8QoP/HRVoGSTttFQWs6pbQxKDlUUc/SrKgkZJBruWx8pU+Jux5x8YUAtbJGGVYSA578CuS+Cs6W3i24s52HzwuqZ7nIOPxAz+Fdj8Zhiw05v9qQfoK8/8M2Uz3NxqNr/AKyzCu2PTcMH8D+ma4Ju2IPrcNBTye9+6/E9Tg2+HPEZjc4sLr7p7Lzx/wB8k4+hrr/NiHQiucu4YfEXhhLq2X98F8xV64YcMn8x+VT+FtQW90tPMQtLF8jN/eGOD+X65r2aj9rBVeq0f6M+Gpx9lUdF7br9UeM+JmH9vXpH/Pd//QjXsngof8Uppo5/1Wf1NeMeKzjxHqK4xi4k/wDQjXt3hFCnhfTASFH2dD+YzXjYX+JI+5z/AEwVH5fkae0A9D+def8AxdYfZtPH+/8AyFehbxjCjd7mvPPjEpFjp7kY+Zx+grpxP8Jni5L/AL7Tv5/kyj8FcHxNcHri3b/0Ja97tuleC/A5C2u3zjtBj82H+Fe82o45NXgP4SObiv8A35ryRdWlpF6Utd58kFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZWqnbIMHqOlatZGtEBwTjp3ppXLhuYV5g8jnNYWpTCCMuQcDk4B/z61u3eTjPXviuW1yVixhRFKZAIcYDc84rlow56qR6sNIlDy59Rnih+zyRurKcEfdXnBz0OcfrXaQxkQqvIVVAA+lHmlRxlh6YplxexwW8k0p8uOMFmZuwFaVa3tLK1kjeMGhzHBxtFG/B+7+RrnohqGrM0sWoLZZG6KBVBbb2Z++T6Vq+Hb77fp3mSqqzxu0MoHTepwce3es1FuPMhykoy5HuZfxB/eeDtQG45Cq2D7OK8v+GKM/jK029VDn/x017B4uhW48MapGBkm3cjjuBn+leV/B+DzfFTyY+WK3ZvxJA/rXn11evA+qyqqlleIXa/4qx7ORKO9Ad1++vFS5AFMMq/Wu4+UvfofP3jv5fFupj/AKbE/ng17d4TUR+GNLHT/R0/9BFeNfE6MR+MrsqOJAjj8VA/pXt2kxrb6ZaQHgxxKh/AAVw4ZWqzPq88mpYHDeav+CLRUHkcVg+O42bwhqY6gRbvyINdFwBntWV4nQT+HNTj65tpP/QTXZUV4tHzeEny14S7NfmeOfC9d/jOzyM7Vc/+OmvdOT93ivEvhGu7xaXwT5du7fqB/WvbQXbtiubBfw/me5xO74xLtFfqIVkPcV4x8X0ZPEyFv47dT+rCvadn+0c15L8a4it/ps3XfE6Z+hz/AOzU8Yv3TMuHJ2x0V3T/AM/0Or+FpMfg61JU4ZnOf+BEV2AYEcGuf8CxraeENLiYcmEOf+BfN/WtvzEJ+7W1JWgl5Hm5g/aYqpJfzP8AMkkClSDXzY0WNa8n/pvsx/wLFfSSshNeEyWG/wCJhtAODqGcf7O7d/KubGxvy+p7nDNVU/bX/lv91z3OOEBFGR0qRdinAxmozCoH3iBSxhF+6M+5rtPmHr1OE+MyZ8P2jj+GfH5q3+FYvwbt0uX1dZRujZFRh6g5yK6f4sW/neD55AOYpEf9cf1rH+DEEkel6hcKmRJMEz/ujP8A7NXFKP8AtKPqKNVf2HNLvb8Uy94T87RvEd5ok0reU5LxFj94gZB/FevutXrFG0rxdNa7isF2NygdM8kfqGH41W+IEU9vLp+rwqFmgkCH/a/iX8OGH/Aqd4sd8aXq8LAqcFSO/R1/k1enhdZOn3/pHyuPvyRr9Vv+T/A8v8bp5fi3U1/6bsfzOa9s0KVf7H0+FF3bIEBx67RXiXj1xqPje5j09w6TNGPMHQkgDj8a96s7WLTrWOKNwqqoXLdTivMw0Wqkz6nPK0ZYTDryv+CLAdh/yzArg/jGpbw9aS4IxcY/NG/wrvBICOelcd8VkM/hCdgvEUiP+uP610Yhfu5HkZRPlxtJ+f56GD8EEdrrVXjzlVQZHuT/AIV7npokEK+actXkHwJttmmajct0knCD/gIz/wCzV7FangYFVglakjHiipz46ol0t+SLy0tIvSlruPlQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArK1uIvGWUZZRkCtWql5nJxRe2pdPc4HUL8QhwyscnaTuKnJ7D3zWRYW51LUt8iA28T7iWB4bOcAH69c10mtRabJcbri5gilBGf3oUn61LaQwR2yJbpGIQPl2dMUnUhBNwXvM9WnF21JgB2ArnfGERvFsdLjYob2bDsOuxRub+ldBt29GxXP6if8AistHVmz+6lK/Ur/9auVnVT+K5V8RaLYadpD3lmrQXdoPMjkDkknPfPXNTeBombQRPMcSXMrzEfU4/pUXjVvtDWmkQkmW6cM+OcKDxn8efoprpLe2ht7eOGJQEjUIo9ABiuuUmqCi92/wOKCTruS6L8QuYBLayws3yyIUP0IxXnXwj0uawk1Se7ieMllhXcMZwTnHt0r0gRpjnP4mnLGi9FFcEqalJS7HrUcbKlQqUFtO34EWYyehp6iI04sg9KMofStDkueY/ETRJrzxro8lvA8kU4RHKrkDa/JPpwRXpfmIOCMYp7KAMjNN3ofvLg+4rOFNQk5LqdeIxksRSp0pLSCsJ5kfQEn6VHcxpNbSxEMFkQoePUYqwmzHy4pC6g4Jwa0OROzujzD4SaVPZXup3F1DJGVAhTcpG45JOPyFenjIHLU1jGerD86BGh56/jWdKmqceVHXj8ZLG1nWmrXt+ANIg4JzXHfETw9L4htbJbLYJYpTkucAKRz/ACFdoEUdFFISo64qpwU48sjLC4mWFqqrT3RBZW8NvaQwIPljQIM+gGKscAHgGmtsPJOKQGPnHNUtDFtyd2J5kZHIxXEjwzKfiG+srtNpt3gA879u3p+tdsDFnp+dSrt/hx+FRKCna/Q6KGKnhubk+0mn6MrCCQncWP0NSBypw64HqKkYN/CaZ5mOJAPrVnPdy3M3xTZf2t4dvrKMjzJYyEzwNw5H6gVS8CaUdD8PRWlwy/aC7SSbTkZJ/wAMV0A8tumD9KGiUjgAGp5Fzc/U3WJmqDw/2W7/AD2MbxpCtx4Yvh3RRKD6bSD/AErgb+9l1LwpY6VaZaWNS87j/llGrlR/47/MetegeKZHj8N6mGXINu4z9RiuY8F2cf8Awi2qSFB5t0HUNjnAXA/XNVB2qIVv9nl+H3HNXXh2a71fw8NDEbNHCn2hmONhRvvH1Jr06z0do3826uHuZj1Zzx+ArK8DJGdMmkSMGRpSGb2wCB+v610ogc/xEe1a1YxozlGmrXepisRVxVKm67vyqy/ruOWED7zVQ8T6YdV8PX9lEB5ksZCZ/vDkfqBV7a6npupwkk/551i0mrMuE5U5qcXqnf7jP+HehyaD4fhtLkqbgu0km05GSe34YrubfoKwrUyMRkYrctRgcmtaUVFKKODH1ZV6kqs3q3cur0paRelLW55YUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVkaupuZTbB2RMbpCvUj0rXrE1F2W9lSPHmSBdpbpwDmixcHaSOfvfDumSKVe3Vs9yxz/ADrlNS0GLRi1zperjTWznZNIBG359fxBrqNRsNVlfEeoxwoepWIE/h/+us5PCWmmQy3glvLhvvSTSE5/AcYrlnHse9h6rS96X6mXofi5LmYWuoywxzZ2ieM5ic/Xt/L+VJ4vmax1XRdRdj5UUpV27YOP6bq1b3wppFxCU+xxxHs8I2MPy6/jmuA8a+H7rSrWGCxup7iCZ8C3yQwx1O3oeuOMHmpUZS0R0qdG/Nex1/htTqer3usuCyltkBPQLjj9P/QjXUbc/ekx9OK5D4carE2nJpMpVZ4QSnbeucn8QT+X412flrnjitalT2krrY440XQ9yW5C0QJ+Q7vqacRKwxjFOK4PzLkeopyhexNZl8xGsJ/ib8qXy0B+9z9aczEfeXK+opdqMMgAigV31BQR0IIpzKGHIqJ4scoSD7UwPKvX+VAWvqmPMA7Eik8j1c0qF3/iAqRUA680A211GeSuOppBFt+6cVI3+yQKaCR94ZHqKAuxPL9WNHkjPUgU8Y7GkBbPIH1zQK7EESDsTS+Wn92glvQfnSNvI42g0Br3AxJ6U0wD+FiKaXkU4bFPXc3Vhj2oHquogh9Xal8lSMHJFPCgdeaRif4SKLC5mR/ZwPuMVpfKb/noaN0oPRW+lHnEdUNA/eMjxhHt8M6gS5P7vH5kVD4F2r4VtAVySZM8df3jUzx3clfDF0u3l2jUf99j+gNWvCCSR+GtPGAA0Qf/AL6O7+tT9o219jr3/Qz/AIfyCOzu4WOCsoPP+6B/7LXVlgPpXJ+DU/0zV0yMLIv83/wrqfKx9w49q6sV/Ff9dDgwqXsl/XUcVDDimhXU5U5HpUZaSM/dyvtUiSs3Koa5zos0W7V23YIwa2rXoMmse23EjKitm16DitYHBiS6tLSLS1seeFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYXiGCTclzb58yPsBnP4d63aq3YPOKTly6sqCuzgrjxNbROVvLeVGHBaP5h+XUflTI/E+jvwLvYf+miMuPzFbuqWMF2cXNvE/u6AmsG48NaU5P+iMp9UkYfoDikpUJb3+R6EFWS91p+poWt/aXWTa3EcwHJ8tw2Pyrn7jbf+OIkdSY7SHfgjv1/my/lVS/8JtEwn0m5cTLyFc7W/wCAsMY/Go/B0txc+IrqS8fM7QkMSNp+UqvI9eBmtYU4RjKpTlfT5inUk5Rp1I21+RV8eWA0+9g1fTsxOz/PgY2ydQ348g//AFzXa6RfDUtNtruNMCVAxHoe4/A5FVPF9ms/hfURjlIjKPXKfN/SqXwzYzeHpkY8QTsoH1Ab+bGvFqYylSb1vbex6s5KVFSe6djpMvnhfzNBLDqF/OrkcAC5A3c5qN4VLEqhBrGOaUm/eTRyKorlYSf3lIHr1FIVjJyp2n2OKsPEyEZwKkW2JTdjNbyxtGPW/oPnSKeGHSQn6ijMnoCPerBQAgZ69Kl8gFSQaw/tSheyuPnXUoFc/eQfgaAkZP3j9Can8iNj84wPWnCxVmODwO+a0jmNCez/AAH7SK3ZCFjHTn8aNzZwgXH1p7Wyg4OfzqIjy/lUYJOAfataOLpVnyweo00xxZh1C/nQJB/EpH4U9IwOg59aeIznHSqniaVN2lJJibRHuB6EUhJ7EflVs22E3EHFRhAW259/wrmnmdCPf7iVNPYrZkPVRj3NNKg8smPcGrzwAJkH8KhW2jY/MMehpLM6D3umNVEQBEP8R+hNOwi9qmFiCC3Ye9MForHAyT9a0ePoJpX/AAY+eL6jQyY64/SggHo5pDER0Y/Q0gQE4ZfyrsjJSV1sPQ4/4kSubGyso2DTTzZUeuBj+bCurtYvstrDAjLsiQIv0AxXG2oTX/HrSoC1pYDg9iVJAP4sSR7LXeeQF5KgYGawqYinSfvu1zaq1CMYP1+85HwcxOoawwJwZB0H+09dWCcdGrmPAKM9re3GCPMlA6e2f/Zq6po3Azk4rpxWJoqu4uSvp+RwYVr2S/rqRjeO2R+tIrKDyrL+FH71T/Cw/I05JlLbWBVvQ0jpLlpgkYfNbVt061iWw+cevY1tWv3a2gefiS6tLSLS1qcAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVXuec1Yqvc8ZrHEfAyobmVMR5hB5FRSQI+SAM4qa5QOeSQBzxVR9yNlXyPevk675ZO6PRhqtGV5oB+PbHUVyM6Cz8cWzrx56ZfHckFf/AGVa7qKNZCTIwri/EaA+L9KSP7wwfwDE/wBDXq5Ti6nM6Utbp2+7qFad4pdU1+Zua6gOg6nv6C2lwPX5DWH8LwF0O7znLXOB+CLWp4uu1t/C2obmwXTylHruIX+RNV/Adotv4fs2+68weY++TwfyxXhpuFJvq38/M7V/Bd+r/I6GR3gP8W3rleafEXkG4bhnoTRI3BJxwKkhuBHnvWcOVys3ZHM720WpDMm8ESMdvf1xUvm+XCUTLeg6mmO4d2c4CAZYngVmrrGnWzN5uoWpCnAHmgn8hVQjOT/dpu4m0l7zNCFtg/eDk9akcofusfpWHeeL9GIIWSR2/wBiF/54xWavjCxSQ/ub+RewCoP/AGYGuqOXYl+7Gm2vS35mft6W7kdb8iqRyTUUExjJyp2ZwD2rmJfG1qANlhcn/eKD+tRjxxD91rGcL2wy/wCNaPKsYn8G3p/mSsVRtqzsJWVxlQeap3Axsb0Nc/B43tFYhrK7HuAh4/76p8vizSpUyTcREc4aIn8OM1rh8FiadaM5Qe/YuGJpJ/EdJDJsJOMnHFSwpucuz/NjpWFaa9pc2Nt/Av8A10Oz/wBCxWxC9tcxbre4jkHTMcgaufG4SdGs7q6369TRzg9mT3EreXsT5j7UyFgihZB25+tJabkGWG4k0+5xJ/CVPqOK4m2/3jevYLJe6I2wn5WY0khQRlV5NJaw/Nh5C2emfSprmMRkdCKfK3FzsK6TsQQXBQAOpCnoT3FPOWYeWD60wMHYxuwGOnvToJWUnCgY4z2NCl9lvQprqhjLmRt4wRXO+MdZTTdLdIT/AKZcZjiC9QO7/hnj3xV3xLr9po8DSXDB7hhmOAHl/r6D3rn/AA1pVxqOof29r6ksSGt4WBwPQ47KOw/Gt6Upx96UmorY3pQsvaT2/M1vCGh/2Fpa+cMXUwEkg/u+i/h/MmtDxFcNY6HeTZ5KFE9i3A/nWnHEbnDk47gVxvi2WbUtZtdGtmyA2+Xac7Sf8FyfxFbYWEsTiFUqfCtfRI5MVWbi2/iZq+D4BB4etwB80paU/ieP0ArbJMSc/dP6U2FPJiSONQqIoVQOgA4FE26QYY4zxn0rlxFV1asqvVsdOHLFQ7E3lI0XygZFVpIlb5WHPUU8BomAR8r71PFGrgl2GaqjUlGSdPRoq/LrchtsggHqOQfUVuW3TNZKLzx2Natp93FfWYWsq0FNHPiHdXLq9KWkXpS11I4AooopgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVXue9WKguBnNY1/gZUNzKnODgVTLMu4FQVOcVcuW2N0FUrmUv2xivj8XKzfc9KkrjYo2KgB+a5Ut9s8aSyjmOwi2ZHduRj/x5v8AvmtbWtTi0iwdjNGboj93Du+Yk+3XA71wdlr8mlWE4SBTK7F5Jpmz+QHX16jk16uS4SprW5fJfPd/L9TOtWh7SMW+t/8AI1PiBcNd3OnaTbn95K4dvYk7V/mx/CumlvdM0qCJJrpVeFAiRRncygDAGB/WvKVu7jUdRkv7t8P1JB24OMAfQCtax0+7vIy1nbO0QGTIcJGB67jgV1f2ZGu3VxE7Ru/6ua47Fuk1Qpq7W/q+h1Vx41QHFrZNJx96Zgg/IZz+lYt34k1W5JAuFgQ/wwIF/U5P5Gsa5lsLNiLi9FxJ0Mdivm4+rnCj9apNqi8i3s4l9HuZDK3/AHyNq/mDVweXYfSEeZ+l/wA/0MIYLHYjW1l9xcuZzM/+kzPM/X965c/rVCbU7a3YqWZm/uohOKpXUxlG26uWZSf9UuET8EXA/StTTtA1e8jBsdJmER/jlAiX6/N1/CtJZryr3Y2X9eh1xySENa9Qp/2wHz5dpcn/AHlA/rSf2lcdrJse7iuhg8Da0ZQs09hDn/adj/IVpR/Dy+f/AFmqwJ/u25b/ANmFcn9tSfVfcavLsBDdtnGHULs9LZB9XpDqF4BkW0J+sh/wrun+HDDaG1liT122wH/s1Pj+GytHufVZ89cCJaj+2at2lL8P+AP6plyWz/E8/Gp32f8AjygP/bcj/wBlpkmq3wHOnx/8BuM/zUV6DH8O4ixU6ndfXy0/wpk3w5jXBGqzn6xLVUs4qSko82/kP6pl17cr+9nBJq9znDaY4x3EymnHWAGHm6bdbuxCq2PxBrsZfh+4ZBHq5yT/ABWwP/s1B+H9+xPlalbNg/xwMv8A7Ma3rZzOE+WTQSy/APujmbXxbcWePKk1eEDplWKj8MkVr23xKnTAlu45f+vi2ZT+a4FWLnwFr0a5WTT5B2+d1P6rWa3hXxDG7KNOSUj+5OnP54rmqY+hU0qQixRy/DPWFVo6TTviRYlVW6EQI/ijnUk/g2P51vWfjHRr0jdeeUfR1OPzGR+teaT6Fq6f6/RLsj/YjEn8s1k3mnJGT9q02aIj/npbsv8ASuedLCT2i16P/O5osA38NVP1X+Vj3mXUtOSza5W+tmhHLOJAVH41yV94ymvZfsXhu2knuWyPNZOAPUA/zbA+teWRyWEC7Vmijb3bBH51o6Vqt3YIyabqcsSsdzBWVgx9TkVzvCqMnJfK5008Dyx1ak/wPSvDfhPZeG/1+T7XeltwUncqn1Oep/QV2kjJISqA4xg5rxeHxX4gjyw1IOT/AH4E/oBVuDxpr8RY+faOT13Qf4GsvY1ZOzasZVcFXm+ZnonifVk0SxG3abmQYiTP/jx9hVLwbpT2qS3l8D9snOSW6hTzz7k8n8PSvNJdc1WXU/t00lvcXAOQZIyQPTAz27VrDx1ruNpaxA7fuG/+KrsqRVOl7Gh13b/JeX5nLHLMRKXPNbba/ieu3KoI1KHnvUSMGG1uPT3ryJ/GWvOTi7gUf7MA/qarXHivX5FwdVZV/wBiGMf+y1xvDzcubRG8cuq2sz2aSAbMjp6U2GPIxuOfevD5fEWrOMT63ernsswT+WKpNd/aJMT3txcE9nnZ8/rVfVLu9y1l9RL3pI+gHngt2AmuYUPozgVo2d3BIB5cqv8A7vNeLeGrR3kXyLKdh6iE4/PFeraDbTog3wlP97Ar3cu92Ditkedi6Cpr4rnSoQRxTqZGCFGafXpo8lhRRRTAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqreSxwqWkdVHqxxVque8RoXchQWbHAAyazqx5o2HF2Zha74lgh3LbwtcP6k7U/Pr+lcVqmv6jeEh7jyY/+ecA2D8+v61c1tY7dz9su7e2HoT5j/8AfC/1IrDbV9MtRm10ya+m/wCel6wVAfZB1H1/OuCMsHh9eXml9/56HVDDYrEaQ0X3EdlZ3N5IRY20twxPLIuRn3bp+ZrF1uSSO7MMrxmOI4YRNv3P6ZHBx7Z5+lXdV8Qanfxlb29MVtjHkQfuowPTjk/jVTTNNvtTH/EtspJIxx5hGyMf8CP9KUswq1moRVk/63/4B6+CymOGkqtZ6rYuLrMVtEkWkaZChX/l6vB5khP94J0U1Qvb+5vnC6heT3bk8RuxIz7IOPyFddpfgF2RZNYvSAf+WFsMfgWPP5AV2OkaJp+koTZWkMHHLAZY/VjyazxFOMv3lV2t1Ot1aFFt043fc8z0vw1rOormCy+zQ/8APS6/dj8F+9+ldXpvw5tVjEuqX01w3eOL92n+J/MV28IR1yD1/CnNHn7px7dq8OdW8uWMtO9v+HZzVMZVm7XsZel6LZaa2bKytYT0Dqnzke56/rWs0rFdvNMG9R0BqLzV8zJ4I7URwVWrfkkn8znd5u7J2t/NXknHtUJWaNsB9w9xU6y/L8rcUBhn7wzXI6LeiTuiU2tyOCUEkSkBs9MY4qYS/MduCvYCo5IxIQWAIByAfWpI3WJCDEDnuKIS5dGKST1QBS5wfkTvjqajkxtx6cUbtx7gUgJLgKpI7+xp+01TS2ElYqSA4DL95TkVLDcKzdcN1weKklQ7xtUgmmNCRy0YPvivSr4eOLaqUppN9Gza6ktSw8hkAGeKa9vv+bcwPUY7VArbeg4qZLgYw3864qmDrQm1Ui35ohxcfhIszISNwYfT/CpreVSo8wjd3FOWREBwvWoSEZtzKpIGBntWfsZx96CbXoD97dC3dtbXgKywwyqeokQN/Osa68DeGrpWM+kWSse8UYjP5rit9ZlWLaI+fUUzdu65HtThWlB3jLXyuiNdjhbn4ZaTIx+wySQH+62WH6EH9aydQ+G93aKWjiM69QYbtwfyYj+Zr1CMt5hKqSOuadM8kuYxkMR1PQV3Uc1rQTU0pdrpf8ORKEr+7Jr0bPE5fD/2UH7TBfQgdTIzgfmeKgbSbV8FZJ/qJTXuPz26BXJcAYz0OKzrzQdP1EbnsoQ7dXA2N+a4NehTzqi/dqUfut+T/wAzGdPEbxqv72eXWFrYwYE2nW9zjvJJKCfyfH6VrQ3OhRn954ZtfqJd/wD6EK6ibwPakfu57mFvQMGH6jP61Sk8DyZ+TU0Hs8H9Q1dDxOWVfjTi/mvyMXPGp/E38yhBqnh6MZHhyFXHcQxH+daln4xtLZcWulPF7LsUfpVSbwXdoQEvbZ8/7DD+tJb+D7xsFruBfpGT/WptlSfx/jITni5LVfkbdp4qeaT5LJVz3aXP6Yrp9MvprgAsEUewrmdP8LmIjzL3cf8AZh2/zJrrtN0+O3UAM7H/AGj/AIV14R4a7VDb5/qS1Vt75rRHK80+moABxTq7TEKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKhuLWG4UiaMOD1B71NRSaT3BOxjSeGNFkyX023Ofaoj4Q0A9dKt/yNb1FR7KH8qNVXqraT+8wIfBvh2GcTJo9p5g6Fk3Y/OtU6fakAGBMDtirVFCpQTuoq4nVqPVyf3lb7Ba/88E4oNjbH/lin5VZopypQn8STF7SXcrmyti2TCmfXFKLSAZ/dLU9FR9Xpfyr7kLnl3IPsdv8A88lppsbYnJhTNWaKcaNOLvGKXyDnl3K5s7Y9YVpPsFr/AM8EqzRVRpwhpFJD9pLuVhY2w6QrTvsdv/zyWp6KUqNOWsop/IOeXcriyth0hQfhSraQKcrEoqeip+r0v5F9yFzy7kJtYCcmNc0n2SD/AJ5LU9FP2FL+Vfcg55dyt9gtf+eCflR9gtf+eKVZorSyH7SfcrfYLX/nglAsLX/nilWaKLIPaT7lb7Da/wDPFKUWVsOkKflViisnh6Td3Ffcg9pLuQrawJ92JRSfZIM58pc1PRR9Xpbcq+5C55dyF7WBx80amhLSBPuxKKmop+wpXvyr7kHPLa5E1vExyYwaabO3PWJanoodCk94r7kHPJdSt9htv+eK04WkAGPKXH0qeiksNRW0F9yDnl3IRawL0iUVII1HRRTqKuNOMPhVhOTe7CiiirEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fractional photothermolysis involves the delivery of narrow columns of infrared light to the target tissue. In skin, this leads to microscopic columns of thermally damaged tissue (microthermal zones).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_15_39153=[""].join("\n");
var outline_f38_15_39153=null;
var title_f38_15_39154="Phalanx fracture traction and reduction";
var content_f38_15_39154=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F68434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F68434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Phalanx fracture reduction: Traction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Reduction of a middle phalanx fracture is performed by applying longitudinal traction (shown above), and then using three-point pressure to bring the distal fragment into alignment with the proximal fragment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_15_39154=[""].join("\n");
var outline_f38_15_39154=null;
var title_f38_15_39155="MRI brain Chiari II malformation";
var content_f38_15_39155=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F61496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F61496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intracranial MRI findings of a child with a Chiari II malformation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 431px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A sagittal T1-weighted MRI in a pediatric patient shows several characteristic intracranial findings of the Chiari II malformation, including downward displacement of cerebellar tissue through the foramen magnum (white arrow), a small fourth ventricle (yellow arrow), and tectal beaking (pink arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D Schwartz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_15_39155=[""].join("\n");
var outline_f38_15_39155=null;
var title_f38_15_39156="Sulfacetamide and prednisolone: Patient drug information";
var content_f38_15_39156=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sulfacetamide and prednisolone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/54/3940?source=see_link\">",
"     see \"Sulfacetamide and prednisolone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F222189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Blephamide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F222190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      AK Cide Oph;",
"     </li>",
"     <li>",
"      Blephamide&reg;;",
"     </li>",
"     <li>",
"      Dioptimyd&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691501",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat eye infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702968",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sulfacetamide sodium, prednisolone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703763",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have herpes, viral, or yeast infections of the eye.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697926",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bright lights may bother you. Wear sunglasses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705388",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Eye solution, suspension:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695632",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake suspension well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705387",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Eye ointment:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696126",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and to the side of affected eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694922",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gently pull down the lower lid and squeeze in how much the doctor told you to use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Release the lower eyelid and keep eyes closed for 1 to 2 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695617",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 10 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699253",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect eye solution from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11059 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-D8E5382BBA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_15_39156=[""].join("\n");
var outline_f38_15_39156=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222189\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222190\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014018\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014017\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014022\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014023\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014025\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014020\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014021\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014026\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014027\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?3/54/3940?source=related_link\">",
"      Sulfacetamide and prednisolone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_15_39157="Porfimer: Drug information";
var content_f38_15_39157=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Porfimer: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/10/13476?source=see_link\">",
"    see \"Porfimer: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F211474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Photofrin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F211475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Photofrin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F211499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F211478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Photodynamic therapy in esophageal cancer or endobronchial nonsmall cell lung cancer:",
"     </b>",
"     I.V.: 2 mg/kg, followed by endoscopic exposure to the appropriate laser light and debridement; repeat courses must be separated by at least 30 days (delay subsequent treatment for insufficient healing) for a maximum of 3 courses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Photodynamic therapy in Barrett&rsquo;s esophagus dysplasia:",
"     </b>",
"     I.V.: 2 mg/kg, followed by endoscopic exposure to the appropriate laser light; repeat courses must be separated by at least 90 days (delay subsequent treatment for insufficient healing) for a maximum of 3 courses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Photodynamic therapy in papillary bladder cancer (Canadian labeling; not in U.S. labeling):",
"     </b>",
"     I.V.: 2 mg/kg, followed by cystoscopic exposure to the appropriate laser light.",
"     <b>",
"      Note:",
"     </b>",
"     Repeat dosing is not recommended due to increased risk of bladder contracture.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F211479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F211453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Photofrin&reg;: 75 mg",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F13186075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Photofrin&reg;: 15 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F211439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F211456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer slow I.V. injection over 3-5 minutes. Avoid contact with skin during administration. Avoid extravasation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F211505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not mix porfimer with other drugs in the same solution.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F211454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Palliation in patients with obstructing (partial or complete) esophageal cancer; treatment of microinvasive endobronchial nonsmall cell lung cancer (NSCLC); reduction of obstruction and palliation in patients with obstructing (partial or complete) NSCLC; ablation of high-grade dysplasia in Barrett's esophagus",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling (additional use; not in U.S. labeling): Second-line treatment of recurrent, superficial papillary bladder cancer",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F211496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of actinic keratoses and low-risk basal and squamous cell skin cancers",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5977830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F211497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (5% to 31%), edema (3% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (8% to 31%), pain (1% to 22%), insomnia (5% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Photosensitivity reaction (19% to 69%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Esophageal stricture/stenosis (6% to 38%), nausea (24% to 37%), vomiting (17% to 31%), constipation (5% to 24%), dysphagia (10% to 24%), mucositis (&le;20%), abdominal pain (5% to 20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (32% in esophageal cancer patients)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (3% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pleural effusion (5% to 32%), dyspnea (7% to 30%), bronchial obstruction/mucus plug (21%), pneumonia (6% to 18%), hemoptysis (7% to 16%), cough (5% to 15%), bronchostenosis (11%), pharyngitis (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     5% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Atrial fibrillation, cardiac failure (esophageal cancer), hyper-/hypotension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety, confusion, dysphonia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, diarrhea, dyspepsia, eructation, esophageal edema, esophageal pain, esophagitis, hematemesis, melena, odynophagia, weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchial ulceration, bronchitis, fatal massive hemoptysis, respiratory insufficiency, tracheoesophageal fistula",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Hiccups, moniliasis, tumor hemorrhage, surgical complication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Common adverse reactions observed in papillary bladder cancer (Canadian labeling; not an approved use in the U.S.):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety, insomnia, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Bladder contracture (irreversible), dysuria, genital edema, micturition frequency, nocturia, suprapubic pain, urinary incontinence, urinary tract infection, urinary urgency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;5% (Limited to important or life-threatening): Airway obstruction, angina, bradycardia, bronchospasm, cardiac failure, cataracts, cerebrovascular accident, diplopia, erythema, esophageal perforation, eye pain, fluid imbalance, gastric ulcer, gastroesophageal fistula/perforation, hemorrhage, ileus, infusion reactions, jaundice, laryngotracheal edema, lung abscess, MI, ocular sensitivity, peritonitis, photophobia, pneumonitis, pruritus, pseudoporphyria state, pulmonary edema, pulmonary embolism, pulmonary hemorrhage, pulmonary thrombosis, respiratory distress/failure, sepsis, sick sinus syndrome, skin blistering, skin discoloration, skin fragility, skin nodules, skin wrinkles, stridor, supraventricular tachycardia, thromboembolic events, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F211459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Porphyria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Photodynamic therapy (PDT) is contraindicated in patients with current tracheoesophageal or bronchoesophageal fistula; tumors eroding into a major blood vessel; emergency treatment of severe acute respiratory distress when caused by endobronchial lesion; esophageal or gastric varices; esophageal ulcers &gt;1 cm in diameter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to porphyrins; photodynamic therapy is contraindicated in patients with papillary bladder cancer who have received prior total bladder radiation or whose functional bladder capacity is &lt;200 mL and in patients with coexisting bladder tumors of stage greater than stage 1 (T1) who have invasive cancer",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F211443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Airway obstruction: Treatment-induced inflammation may obstruct airway. Use with caution in patients with endobronchial tumors, especially if in areas where main airway may be obstructed (long or surrounding tumors). Necrotic debris or mucositis may also cause airway obstruction. Monitor closely between laser therapy and debridement for respiratory distress; may require urgent bronchoscopy to remove secretions or debris.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chest pain: Inflammatory responses within the treatment area may result in substernal chest pain.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Esophageal strictures: Esophageal strictures may occur, usually within 6 months of treatment. May require multiple dilations to resolve. The risk is increased with nodule pretreatment or with retreatment of the same area.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastroesophageal fistula/perforation: Serious and potentially fatal gastrointestinal and esophageal necrosis and perforation may occur following treatment. Due to the high risk for fistula, do not use in patients with esophageal tumors eroding into the trachea or bronchial tree. Use is contraindicated in patients with existing tracheoesophageal or bronchoesophageal fistula.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemorrhage: Patients with esophageal varices or tumors eroding into pulmonary blood vessels are at increased risk for hemorrhage, including fatal massive pulmonary hemoptysis (FMH). Other risk factors for FMH include large, centrally-located tumors, cavitating tumors, or extensive tumor extrinsic to the bronchus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular photosensitivity: Ocular discomfort has been reported with sun or bright light exposure. For at least 30 days (and until ocular sensitivity resolves), when outdoors, patients should wear dark sunglasses which have an average white light transmittance of &lt;4%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Photosensitivity reactions are common in patients who are exposed to direct sunlight or bright indoor light (eg fluorescent lights, unshaded light bulbs, examination/operating lights). Conventional ultraviolet (UV) sunscreens are",
"     <b>",
"      not",
"     </b>",
"     protective against photosensitivity reactions caused by visible light. Photosensitivity may last 30-90 days. Encourage exposure to ambient indoor light (aids in gradually inactivating residual porfimer). Patients should be educated to test for residual photosensitivity before resuming exposure to sunlight. Re-exposure to general sunlight should be gradual (expose small area of skin [not the face] for 10 minutes, if no photosensitivity after 24 hours, may gradually resume normal outdoor activities; if photosensitivity occurs then wait 2 weeks and retest).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolism: Thromboembolic events may occur, generally in patients with additional risk factors for thromboembolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Barrett's esophagus: In patients with Barrett's esophagus, conduct rigorous surveillance (endoscopic biopsy every 3 months until 4 consecutive negative results for high-grade dysplasia followed by further follow-up per physician judgment). The long-term effects of photodynamic therapy in patients with Barrett&rsquo;s esophagus is not known. Esophageal strictures are common adverse events associated with photodynamic therapy of Barrett's esophagus; esophageal dilation may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Esophageal/gastric varices: Not suited for treatment of patients with esophageal or gastric varices (due to the high risk for hemorrhage).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Elimination may be prolonged in hepatic impairment; toxicities may be increased. Photosensitivity may be increased beyond 90 days in patients with mild-to-severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Elimination may be prolonged in renal impairment; toxicities may be increased. Photosensitivity may be increased beyond 90 days in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitizing drugs: Concurrent use with other photosensitizing agents may increase the risk for photosensitivity reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Radiation therapy recipients: Allow 2-4 weeks to elapse after phototherapy prior to initiating radiation therapy; 4 weeks should elapse after radiation therapy prior to initiating phototherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extravasation: Avoid extravasation. If extravasation occurs, protect affected area from light; use of antidotes is of unknown benefit.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F211448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Photosensitizing Agents: May enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F211450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F211461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have shown maternal and fetal toxicity, but no major malformations. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if the potential benefit outweighs the potential risk to the fetus. Effective contraception is recommended for women of childbearing potential.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F211484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13185708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for adverse reactions in the nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Photofrin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (1): $22324.74",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F211462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Photobarr (CZ, EE);",
"     </li>",
"     <li>",
"      Photofrin (AR, BG, DE, FI, FR, GB, GR, HN, IE, IL, JP, NL, PL, PT, SE, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F211442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Porfimer's cytotoxic activity is dependent on light and oxygen. Following administration, the drug is selectively retained in neoplastic tissues. Exposure of the drug to laser light at wavelengths &gt;630 nm results in the production of oxygen free-radicals. Release of thromboxane A",
"     <sub>",
"      2",
"     </sub>",
"     , leading to vascular occlusion and ischemic necrosis, may also occur.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F211458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 0.49 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: ~90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: First dose: 17 days; Second dose: 30 days",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Basal Cell and Squamous Cell Skin Cancers,&rdquo; Version 2.2011. Available at file://www.nccn.org/professionals/physician_gls/PDF/nmsc.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Oseroff AR, Blumenson LR, Wilson BD, et al, &ldquo;A Dose Ranging Study of Photodynamic Therapy With Porfimer Sodium (Photofrin) for Treatment of Basal Cell Carcinoma,&rdquo;",
"      <i>",
"       Lasers Surg Med",
"      </i>",
"      , 2006, 38(5):417-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39157/abstract-text/16788928/pubmed\" id=\"16788928\" target=\"_blank\">",
"        16788928",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Overholt BF, Wang KK, Burdick JS, et al, &ldquo;Five-Year Efficacy and Safety of Photodynamic Therapy With Photofrin in Barrett's High-Grade Dysplasia,&rdquo;",
"      <i>",
"       Gastrointest Endosc",
"      </i>",
"      , 2007, 66(3):460-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39157/abstract-text/17643436/pubmed\" id=\"17643436\" target=\"_blank\">",
"        17643436",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pereira SP, Ayaru L, Ackroyd R, et al, &ldquo;The Pharmacokinetics and Safety of Porfimer After Repeated Administration 30-45 Days Apart to Patients Undergoing Photodynamic Therapy,&rdquo;",
"      <i>",
"       Aliment Pharmacol Ther",
"      </i>",
"      , 2010, 32(6):821-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39157/abstract-text/20629974/pubmed\" id=\"20629974\" target=\"_blank\">",
"        20629974",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9791 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-D8D1174216-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_15_39157=[""].join("\n");
var outline_f38_15_39157=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211474\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211475\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211499\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211478\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211479\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211453\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13186075\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211439\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211456\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211505\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211454\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211496\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5977830\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211497\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211459\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211443\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299910\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211448\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211450\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211461\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211484\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13185708\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323709\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211462\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211442\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211458\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9791\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9791|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/10/13476?source=related_link\">",
"      Porfimer: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_15_39158="Electrocardiographic characteristics of the short QT syndrome";
var content_f38_15_39158=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electrocardiographic characteristics of the short QT syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 426px; height: 593px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) A 12-lead ECG showing ECG characteristic of SQT1.",
"    <br>",
"     (B) A 12-lead ECG showing ECG characteristic of SQT4 displaying combined ECG phenotype of Brugada and short QT syndromes. Note that ECG shows Brugada type ST elevation in V1 and V2 after administration of ajmaline in addition to short QT intervals.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Patel C, Yan GX, Antzelevitch C. Short QT syndrome: from bench to bedside. Circ Arrhythm Electrophysiol 2010; 3:401. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_15_39158=[""].join("\n");
var outline_f38_15_39158=null;
var title_f38_15_39159="Bleomycin: Drug information";
var content_f38_15_39159=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bleomycin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/49/26388?source=see_link\">",
"    see \"Bleomycin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/33/15895?source=see_link\">",
"    see \"Bleomycin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F141845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Blenoxane&reg;;",
"     </li>",
"     <li>",
"      Bleomycin Injection, USP",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F141887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Antibiotic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F141849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     The risk for pulmonary toxicity increases with age &gt;70 years and cumulative lifetime dose of &gt;400 units; 1 unit  = 1 mg. Details concerning dosage in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Test dose for lymphoma patients:",
"     </b>",
"     I.M., I.V., SubQ: Because of the possibility of an anaphylactoid reaction, the manufacturer recommends administering 1-2 units of bleomycin before the first 1-2 doses; monitor vital signs every 15 minutes; wait a minimum of 1 hour before administering remainder of dose; if no acute reaction occurs, then the regular dosage schedule may be followed.",
"     <b>",
"      Note:",
"     </b>",
"     Test doses may not be predictive of a reaction (Lam, 2005) and/or may produce false-negative results.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Hodgkin&rsquo;s lymphoma (unlabeled dosing; combination regimens):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      ABVD:",
"     </i>",
"     10 units/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1 and 15 of a 28-day treatment cycle (Straus, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      BEACOPP:",
"     </i>",
"     10 units/m",
"     <sup>",
"      2",
"     </sup>",
"     day 8 of a 21-day treatment cycle (Dann, 2007; Diehl, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Stanford V:",
"     </i>",
"     5 units/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose in weeks 2, 4, 6, 8, 10 and 12 (Horning, 2002; Horning, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Testicular cancer (unlabeled dosing; combination therapy):",
"     </b>",
"     I.V.: 30 units/dose days 1, 8, and 15 of a 21-day treatment cycle for 4 cycles (Culine, 2008; Nichols, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Ovarian germ cell cancer (unlabeled use; combination therapy):",
"     </b>",
"     I.V.: 30 units/dose days 1, 8, and 15 of a 21-day treatment cycle for 3 cycles (Williams, 1994)",
"     <b>",
"      or",
"     </b>",
"     15 units/m",
"     <sup>",
"      2",
"     </sup>",
"     day 1 of a 21-day treatment cycle for 4 cycles (Cushing, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Malignant pleural effusion:",
"     </b>",
"     Intrapleural: 60 units as a single instillation; mix in 50-100 mL of NS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in obesity:",
"     </b>",
"     Adults: Fixed doses (dosing which is independent of body weight or BSA), are used in some protocols (eg, testicular cancer); due to toxicity concerns, the same fixed dose should also be considered for obese patients (Griggs, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F141871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/33/15895?source=see_link\">",
"      see \"Bleomycin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     The risk for pulmonary toxicity increases with age &gt;70 years and cumulative lifetime dose of &gt;400 units; 1 unit  = 1 mg. Details concerning dosage in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Test dose for lymphoma patients:",
"     </b>",
"     I.M., I.V., SubQ: Because of the possibility of an anaphylactoid reaction, the manufacturer recommends administering 1-2 units of bleomycin before the first 1-2 doses; monitor vital signs every 15 minutes; wait a minimum of 1 hour before administering remainder of dose; if no acute reaction occurs, then the regular dosage schedule may be followed.",
"     <b>",
"      Note:",
"     </b>",
"     Test doses may not be predictive of a reaction (Lam, 2005) and/or may produce false-negative results.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Hodgkin&rsquo;s lymphoma (unlabeled dosing; combination regimen):",
"     </b>",
"     I.V.: ABVD: I.V.: 10 units/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1 and 15 of a 28-day treatment cycle (Hutchinson, 1998)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F14717786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. The incidence of pulmonary toxicity is higher in patients &gt;70 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F141851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     The U.S. labeling recommends the following adjustments (creatinine clearance should be estimated using the Cockcroft-Gault formula):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     40-50 mL/minute: Administer 70% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-40 mL/minute: Administer 60% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-30 mL/minute: Administer 55% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-20 mL/minute: Administer 45% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     5-10 mL/minute: Administer 40% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     The Canadian labeling recommends the following adjustment: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;40 mL/minute: Reduce dose by 40% to 75%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     The following adjustments have also been recommended:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aronoff, 2007: Adults: Continuous renal replacement therapy (CRRT): Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kintzel, 1995: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     46-60 mL/minute: Administer 70% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-45 mL/minute: Administer 60% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Consider use of alternative drug",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5526919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied); however, adjustment for hepatic impairment is not necessary (King, 2001).",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F14717181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Pulmonary changes: Discontinue until determined not to be drug-related.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Pulmonary diffusion capacity for carbon monoxide (DL",
"     <sub>",
"      CO",
"     </sub>",
"     ) &lt;30% to 35% of baseline: Discontinue treatment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F141823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 15 units, 30 units",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F141808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F141827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V. doses should be administered slowly over 10 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M. or SubQ: May cause pain at injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intrapleural: 60 units in 50-100 mL NS; use of topical anesthetics or narcotic analgesia is usually not necessary",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F141895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, aztreonam, cefepime, cisplatin, cyclophosphamide, doxorubicin, doxorubicin liposome, droperidol, etoposide phosphate, filgrastim, fludarabine, fluorouracil, furosemide, gemcitabine, granisetron, heparin, leucovorin calcium, melphalan, methotrexate, metoclopramide, mitomycin, ondansetron, paclitaxel, piperacillin/tazobactam, sargramostim, teniposide, thiotepa, vinblastine, vincristine, vinorelbine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Cisplatin, cyclophosphamide, doxorubicin, droperidol, fluorouracil, furosemide, heparin, leucovorin calcium, methotrexate, metoclopramide, mitomycin, vinblastine, vincristine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F141826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of squamous cell carcinomas of the head and neck, penis, cervix, or vulva, testicular carcinoma, Hodgkin's lymphoma, and non-Hodgkin's lymphoma; sclerosing agent for malignant pleural effusion",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F10192931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of ovarian germ cell tumors",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F141898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Bleomycin may be confused with Cleocin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F141885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pain at the tumor site, phlebitis. About 50% of patients develop erythema, rash, striae, induration, hyperkeratosis, vesiculation, and peeling of the skin, particularly on the palmar and plantar surfaces of the hands and feet. Hyperpigmentation (50%), alopecia, nailbed changes may also occur. These effects appear dose related and reversible with discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Stomatitis and mucositis (30%), anorexia, weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Tachypnea, rales, acute or chronic interstitial pneumonitis, and pulmonary fibrosis (5% to 10%); hypoxia and death (1%). Symptoms include cough, dyspnea, and bilateral pulmonary infiltrates. The pathogenesis is not certain, but may be due to damage of pulmonary, vascular, or connective tissue. Response to steroid therapy is variable and somewhat controversial.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Acute febrile reactions (25% to 50%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Skin thickening, diffuse scleroderma, onycholysis, pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid-like reactions (characterized by hypotension, confusion, fever, chills, and wheezing; onset may be immediate or delayed for several hours); idiosyncratic reactions (1% in lymphoma patients)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Angioedema, cerebrovascular accident, cerebral arteritis, chest pain, coronary artery disease, flagellate hyperpigmentation, hepatotoxicity, malaise, MI, myelosuppression (rare), myocardial ischemia, nausea, pericarditis, Raynaud&rsquo;s phenomenon, renal toxicity, scleroderma-like skin changes, Stevens-Johnson syndrome, thrombotic microangiopathy, toxic epidermal necrolysis, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F141830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bleomycin or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F141812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: May cause hepatic toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Idiosyncratic reaction:",
"     <b>",
"      [U.S. Boxed Warning]: A severe idiosyncratic reaction consisting of hypotension, mental confusion, fever, chills, and wheezing (similar to anaphylaxis) has been reported in 1% of lymphoma patients treated with bleomycin.",
"     </b>",
"     Since these reactions usually occur after the first or second dose, careful monitoring is essential after these doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary toxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Occurrence of pulmonary fibrosis (commonly presenting as pneumonitis; occasionally progressing to pulmonary fibrosis) is the most severe toxicity. Risk is higher in elderly patients or patients receiving &gt;400 units total lifetime dose;",
"     </b>",
"     other possible risk factors include smoking and patients with prior radiation therapy or receiving concurrent oxygen (especially high inspired oxygen doses). A review of patients receiving bleomycin for the treatment of germ cell tumors suggests risk for pulmonary toxicity is increased in patients &gt;40 years of age, with glomerular filtration rate &lt;80 mL/minute, advanced disease, and cumulative doses &gt;300 units (O&rsquo;Sullivan, 2003). Pulmonary toxicity may include bronchiolitis obliterans and organizing pneumonia (BOOP), eosinophilic hypersensitivity, and interstitial pneumonitis, progressing to pulmonary fibrosis (Sleijfer, 2001); pulmonary toxicity may be due to a lack of the enzyme which inactivates bleomycin (bleomycin hydrolase) in the lungs (Morgan, 2011; Sleijfer, 2001), If pulmonary changes occur, withhold treatment and investigate if drug-related.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal toxicity: May cause renal toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute), may require dose adjustment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: In children, a younger age at treatment, cumulative dose &ge;400 units/m",
"     <sup>",
"      2",
"     </sup>",
"     (combined with chest irradiation), and renal impairment are associated with a higher incidence of pulmonary toxicity (Huang, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; O",
"     <sub>",
"      2",
"     </sub>",
"     during surgery:  Use caution when administering O",
"     <sub>",
"      2",
"     </sub>",
"     during surgery to patients who have received bleomycin; the risk of bleomycin-related pulmonary toxicity is increased.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F141817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: May enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Filgrastim: May enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemcitabine: May enhance the adverse/toxic effect of Bleomycin. The risk of pulmonary toxicity may be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sargramostim: May enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F141819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3013953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Animal studies have demonstrated teratogenic and abortifacient effects. There are no adequate and well-controlled studies in pregnant women. Women of childbearing potential should avoid becoming pregnant during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F141857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3013955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Bleomycin Sulfate Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 unit (1): $41.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 unit (1): $91.54",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F141821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pulmonary function tests, including total lung volume, forced vital capacity, diffusion capacity for carbon monoxide; vital capacity, total lung capacity and pulmonary capillary blood volume may be better indicators of changes induced by bleomycin (Sleifjer, 2001); chest x-ray, renal function, liver function, temperature initially; check body weight at regular intervals",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F141832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bileco (AR);",
"     </li>",
"     <li>",
"      Blenamax (AU, RU, SG, TW);",
"     </li>",
"     <li>",
"      Blenoxane (BR, EC, EG, ZA);",
"     </li>",
"     <li>",
"      Bleo (HK);",
"     </li>",
"     <li>",
"      Bleocin (BG, CL, CZ, EE, EG, GR, HK, HN, HU, ID, IN, JP, KP, MY, PE, PL, PT, SG, TH, TR, TW);",
"     </li>",
"     <li>",
"      Bleocin-S (MY);",
"     </li>",
"     <li>",
"      Bleocina (UY);",
"     </li>",
"     <li>",
"      Bleocris (PY);",
"     </li>",
"     <li>",
"      Bleolem (CO, MX, TH);",
"     </li>",
"     <li>",
"      Bleomax (MX);",
"     </li>",
"     <li>",
"      Bleomicina (ES, IT);",
"     </li>",
"     <li>",
"      Bleomycin (AT, CH, DK, FI, GB, NO, SE);",
"     </li>",
"     <li>",
"      Bleomycin PFI (IL);",
"     </li>",
"     <li>",
"      Bleomycine (BE, FR, LU, NL);",
"     </li>",
"     <li>",
"      Bleomycinum (DE);",
"     </li>",
"     <li>",
"      Blexit (CN);",
"     </li>",
"     <li>",
"      Bloicin-S (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F141811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits synthesis of DNA; binds to DNA leading to single- and double-strand breaks; also inhibits (to a lesser degree) RNA and protein synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F141829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: I.M. and intrapleural administration: 30% to 50% of I.V. serum concentrations; intraperitoneal and SubQ routes produce serum concentrations equal to those of I.V.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 22 L/m",
"     <sup>",
"      2",
"     </sup>",
"     ; highest concentrations in skin, kidney, lung, heart tissues; lowest in testes and GI tract; does not cross blood-brain barrier",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 1%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Via several tissues including hepatic, GI tract, skin, pulmonary, renal, and serum",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Biphasic (renal function dependent):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Normal renal function: Initial: 1.3 hours; Terminal: 9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     End-stage renal disease: Initial: 2 hours; Terminal: 30 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: I.M.: Within 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (50% to 70% as active drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 97.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Azambuja E, Fleck JF, Batista RG, et al, &ldquo;Bleomycin Lung Toxicity: Who are the Patients With Increased Risk?&rdquo;",
"      <i>",
"       Pulm Pharmacol Ther",
"      </i>",
"      , 2005, 18(5):363-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39159/abstract-text/15939315/pubmed\" id=\"15939315\" target=\"_blank\">",
"        15939315",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carver JR, Shapiro CL, Ng A, et al, &ldquo;American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(25):3991-4008.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39159/abstract-text/17577017/pubmed\" id=\"17577017\" target=\"_blank\">",
"        17577017",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Culine S, Kramar A, Th&eacute;odore C, et al, &ldquo;Randomized Trial Comparing Bleomycin/Etoposide/Cisplatin With Alternating Cisplatin/Cyclophosphamide/Doxorubicin and Vinblastine/Bleomycin Regimens of Chemotherapy for Patients With Intermediate- and Poor-Risk Metastatic Nonseminomatous Germ Cell Tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(3):421-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39159/abstract-text/18202419/pubmed\" id=\"18202419\" target=\"_blank\">",
"        18202419",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cushing B, Giller R, Cullen JW, et al, &ldquo;Randomized Comparison of Combination Chemotherapy With Etoposide, Bleomycin, and Either High-Dose or Standard-Dose Cisplatin in Children and Adolescents With High-Risk Malignant Germ Cell Tumors: A Pediatric Intergroup Study -- Pediatric Oncology Group 9049 and Children's Cancer Group 8882,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(13):2691-700.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39159/abstract-text/15226336/pubmed\" id=\"15226336\" target=\"_blank\">",
"        15226336",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dann EJ, Bar-Shalom R, Tamir A, et al, &ldquo;Risk-Adapted BEACOPP Regimen Can Reduce the Cumulative Dose of Chemotherapy for Standard and High-Risk Hodgkin Lymphoma With No Impairment of Outcome,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 109(3):905-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39159/abstract-text/17018856/pubmed\" id=\"17018856\" target=\"_blank\">",
"        17018856",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Diehl V, Franklin J, Pfreundschuh M, et al, &ldquo;Standard and Increased-Dose BEACOPP Chemotherapy Compared With COPP-ABVD for Advanced Hodgkin's Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(24):2386-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39159/abstract-text/12802024/pubmed\" id=\"12802024\" target=\"_blank\">",
"        12802024",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Engert A, Franklin J, Eich HT, et al,  &ldquo;Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(23):3495-502.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39159/abstract-text/17606976/pubmed\" id=\"17606976\" target=\"_blank\">",
"        17606976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd JD, Nguyen DT, Lobins RL, et al, &ldquo;Cardiotoxicity of Cancer Therapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(30):7685-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39159/abstract-text/16234530/pubmed\" id=\"16234530\" target=\"_blank\">",
"        16234530",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(13):1553-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39159/abstract-text/22473167/pubmed\" id=\"22473167\" target=\"_blank\">",
"        22473167",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Horning SJ, Hoppe RT, Breslin S, et al, &ldquo;Stanford V and Radiotherapy for Locally Extensive and Advanced Hodgkin's Disease: Mature Results of a Prospective Clinical Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(3):630-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39159/abstract-text/11821442/pubmed\" id=\"11821442\" target=\"_blank\">",
"        11821442",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Horning SJ, Williams J, Bartlett NL, et al, &ldquo;Assessment of the Stanford V Regimen and Consolidative Radiotherapy for Bulky and Advanced Hodgkin's Disease: Eastern Cooperative Oncology Group Pilot Study E1492,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2000, 18(5):972-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39159/abstract-text/10694546/pubmed\" id=\"10694546\" target=\"_blank\">",
"        10694546",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoskin PJ, Lowry L, Horwich A, et al, &ldquo;Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(32):5390-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39159/abstract-text/19738111/pubmed\" id=\"19738111\" target=\"_blank\">",
"        19738111",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Huang TT, Hudson MM, Stokes DC, et al, &ldquo;Pulmonary Outcomes in Survivors of Childhood Cancer: A Systematic Review,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2011, 140(4): 881-901.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39159/abstract-text/21415131/pubmed\" id=\"21415131\" target=\"_blank\">",
"        21415131",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hutchinson RJ, Fryer CJ, Davis PC, et al, &ldquo;MOPP or Radiation in Addition to ABVD in the Treatment of Pathologically Staged Advanced Hodgkin's Disease in Children: Results of the Children's Cancer Group Phase III Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1998, 16(3):897-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39159/abstract-text/9508171/pubmed\" id=\"9508171\" target=\"_blank\">",
"        9508171",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ibrahimi OA and Anderson RR, &ldquo;Images in Clinical Medicine. Bleomycin-Induced Flagellate Hyperpigmentation,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 363(24):e36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39159/abstract-text/21142531/pubmed\" id=\"21142531\" target=\"_blank\">",
"        21142531",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnson PW, Radford JA, Cullen MH, et al, &ldquo;Comparison of ABVD and Alternating or Hybrid Multidrug Regimens for the Treatment of Advanced Hodgkin's Lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(36):9208-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39159/abstract-text/16314615/pubmed\" id=\"16314615\" target=\"_blank\">",
"        16314615",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      King PD and Perry MC, &ldquo;Hepatotoxicity of Chemotherapy,&rdquo;",
"      <i>",
"       Oncologist",
"      </i>",
"      , 2001, 6(2):162-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39159/abstract-text/11306728/pubmed\" id=\"11306728\" target=\"_blank\">",
"        11306728",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kintzel PE and Dorr RT, &ldquo;Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,&rdquo;",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 1995, 21(1):33-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39159/abstract-text/7859226/pubmed\" id=\"7859226\" target=\"_blank\">",
"        7859226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kung FH, Schwartz CL, Ferree CR,et al, &ldquo;POG 8625: A Randomized Trial Comparing Chemotherapy With Chemoradiotherapy for Children and Adolescents With Stages I, IIA, IIIA1 Hodgkin Disease: A Report From the Children's Oncology Group,&rdquo;",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      , 2006, 28(6):362-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39159/abstract-text/16794504/pubmed\" id=\"16794504\" target=\"_blank\">",
"        16794504",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lam MS, &ldquo;The Need for Routine Bleomycin Test Dosing in the 21st Century,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(11):1897-902.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39159/abstract-text/16219896/pubmed\" id=\"16219896\" target=\"_blank\">",
"        16219896",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan C, Tillett T, Braybrooke J, et al, &ldquo;Management of Uncommon Chemotherapy-Induced Emergencies,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2011, 12(8):806-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39159/abstract-text/21276754/pubmed\" id=\"21276754\" target=\"_blank\">",
"        21276754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nichols CR, Catalano PJ, Crawford ED, et al, &ldquo;Randomized Comparison of Cisplatin and Etoposide and Either Bleomycin or Ifosfamide in Treatment of Advanced Disseminated Germ Cell Tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1998, 16(4):1287-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39159/abstract-text/9552027/pubmed\" id=\"9552027\" target=\"_blank\">",
"        9552027",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Sullivan JM, Huddart RA, Norman AR, et al, &ldquo;Predicting the Risk of Bleomycin Lung Toxicity in Patients With Germ-Cell Tumours,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2003, 14(1):91-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39159/abstract-text/12488299/pubmed\" id=\"12488299\" target=\"_blank\">",
"        12488299",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sleijfer S, &ldquo;Bleomycin-Induced Pneumonitis,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2001, 120(2):617-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39159/abstract-text/11502668/pubmed\" id=\"11502668\" target=\"_blank\">",
"        11502668",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Straus DJ, Portlock CS, Qin J, et al, &ldquo;Results of aPprospective Randomized Clinical Trial of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Followed by Radiation Therapy (RT) Versus ABVD Alone for stages I, II, and IIIA Nonbulky Hodgkin Disease,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2004, 104(12):3483-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39159/abstract-text/15315964/pubmed\" id=\"15315964\" target=\"_blank\">",
"        15315964",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tobias JS, Monson K, Gupta N, et al, &ldquo;Chemoradiotherapy for Locally Advanced Head and Neck Cancer: 10-year Follow-Up of the UK Head and Neck (UKHAN1) Trial,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2010, 11(1):66-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39159/abstract-text/19875337/pubmed\" id=\"19875337\" target=\"_blank\">",
"        19875337",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wiernik PH, Hong F, Glick JH, et al, &ldquo;Radiation Therapy Compared With Chemotherapy for Consolidation of Chemotherapy-Induced Remission of Advanced Hodgkin Lymphoma: A Study by the Eastern Co-Operative Oncology Group (E1476) With &gt;20 Years Follow-Up,&rdquo;",
"      <i>",
"       Leuk Lymphoma",
"      </i>",
"      , 2009, 50(10):1632-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39159/abstract-text/19863338/pubmed\" id=\"19863338\" target=\"_blank\">",
"        19863338",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Williams S, Blessing JA, Liao SY, et al, &ldquo;Adjuvant Therapy of Ovarian Germ Cell Tumors With Cisplatin, Etoposide, and Bleomycin: A Trial of the Gynecologic Oncology Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1994, 12(4):701-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/15/39159/abstract-text/7512129/pubmed\" id=\"7512129\" target=\"_blank\">",
"        7512129",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9160 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-74CF0474CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_15_39159=[""].join("\n");
var outline_f38_15_39159=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708640\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141845\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141887\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141849\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141871\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14717786\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141851\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5526919\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14717181\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141823\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141808\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141827\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141895\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141826\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10192931\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141898\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141885\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141830\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141812\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298875\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141817\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141819\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3013953\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141857\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3013955\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323022\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141821\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141832\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141811\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141829\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9160\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9160|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/49/26388?source=related_link\">",
"      Bleomycin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/33/15895?source=related_link\">",
"      Bleomycin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_15_39160="Perianal condyloma acuminatum in child";
var content_f38_15_39160=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83496%7EDERM%2F83497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83496%7EDERM%2F83497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Condyloma acuminatum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Several soft brown papules are present on the perianal skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Condyloma acuminatum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Soft brown papules are present on the penis of this child.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_15_39160=[""].join("\n");
var outline_f38_15_39160=null;
var title_f38_15_39161="Post-remission therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults";
var content_f38_15_39161=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Post-remission therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/15/39161/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/15/39161/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/15/39161/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/15/39161/contributors\">",
"     Bob Lowenberg, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/15/39161/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/15/39161/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/15/39161/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 80 percent of adult patients with newly diagnosed acute lymphoblastic leukemia (ALL) will attain a complete remission (CR) with intensive induction chemotherapy. However, without additional cytotoxic therapy, virtually all of these patients will relapse within a few weeks or months. In contrast, patients who receive post-remission therapy may expect five-year survival rates up to 60 percent in adults with standard risk disease.",
"   </p>",
"   <p>",
"    Induction therapy aims to reduce the total body leukemia cell population from approximately 10",
"    <sup>",
"     12",
"    </sup>",
"    to below the cytologically detectable level of about 10",
"    <sup>",
"     9",
"    </sup>",
"    cells. It is generally assumed, however, that a substantial burden of leukemia cells persists undetected in patients in initial clinical and morphologic CR (ie, \"minimal residual disease\"), leading to relapse within a few weeks or months if no further therapy were administered.",
"   </p>",
"   <p>",
"    The primary aim of post-remission therapy (eg, consolidation, intensification) is to eradicate this minimal residual disease. There are three basic options for post-remission therapy (in order of increasing intensity): consolidation plus maintenance chemotherapy, autologous hematopoietic cell transplantation (HCT), or allogeneic HCT. The choice among these for an individual patient depends upon a number of factors, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Expected rate of relapse with consolidation chemotherapy alone (influenced strongly by the patient and tumor characteristics)",
"     </li>",
"     <li>",
"      Expected morbidity and mortality associated with treatment options (as determined by patient characteristics such as age and comorbidities)",
"     </li>",
"     <li>",
"      Salvage (or rescue) therapies available for the treatment of relapsed disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, a risk-adapted treatment approach is used that offers more intensive therapy to patients with a higher risk of relapse. This topic review will discuss the post-remission therapy for Philadelphia chromosome negative ALL in adults. The following related subjects are presented separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Induction therapy for ALL in adults. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23642?source=see_link\">",
"       \"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Post-remission therapy for Philadelphia chromosome positive ALL in adults. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44489?source=see_link\">",
"       \"Induction therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of relapsed or refractory ALL in adults. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/15/21753?source=see_link\">",
"       \"Treatment of relapsed or refractory acute lymphoblastic leukemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of ALL in children. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31850?source=see_link\">",
"       \"Overview of the treatment of acute lymphoblastic leukemia in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Detection of minimal residual disease following treatment of ALL. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/32/15880?source=see_link\">",
"       \"Detection of minimal residual disease in acute lymphoblastic leukemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/56/31625?source=see_link\">",
"       \"Clinical use of minimal residual disease detection in acute lymphoblastic leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The clinical and pathologic features and diagnosis of ALL in adults. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26007?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of precursor B cell acute lymphoblastic leukemia/lymphoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/20/30023?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK STRATIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;ALL is a heterogeneous disease and outcomes vary by clinical, cytogenetic, and molecular features. Patients should be evaluated at the time of first complete remission (CR1) to determine their expected risk of relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/1\">",
"     1",
"    </a>",
"    ]. In general, patients are categorized as having standard or high risk disease based upon a combination of clinical features and tumor characteristics. While many variations in risk stratification have been proposed, we use the following risk stratification system (ie, a modification of the Hoelzer risk criteria).",
"   </p>",
"   <p>",
"    Patients with any of the following characteristics are considered to have high risk disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High white blood cell count at diagnosis (ie,",
"      <span class=\"nowrap\">",
"       &gt;30,000/microL",
"      </span>",
"      in B-ALL or",
"      <span class=\"nowrap\">",
"       &gt;100,000/microL",
"      </span>",
"      in T-ALL).",
"     </li>",
"     <li>",
"      Clonal cytogenetic abnormalities &mdash; t(4;11), t(1;19), t(9;22), or BCR-ABL gene positivity. The prognostic value of t(1;19) in adult ALL is less clear than in pediatric ALL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Progenitor-B cell immunophenotype (eg, blasts expressing membrane CD19, CD79a, and cytoplasmic CD22, but not CD10). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26007?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of precursor B cell acute lymphoblastic leukemia/lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Length of time from start of induction therapy to attainment of CR greater than four weeks is of lesser importance.",
"     </li>",
"     <li>",
"      Older age &mdash; &gt;60 years old is high risk, 30 to 59 years old is intermediate risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In comparison, patients with none of the above characteristics are considered to have standard risk disease. This risk stratification system was developed based upon analyses of prognostic factors in patients enrolled on prospective trials and many of these characteristics have been used in other prospective trials that have tested a risk-adapted approach to consolidation therapy. The effect of these clinical features on relapse risk is described below. The effect of cytogenetic abnormalities on relapse risk is described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/25/22938?source=see_link\">",
"     \"Cytogenetics in acute lymphoblastic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, numerous clinical models of relapse risk have been developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. The high-risk subset varies somewhat from study to study and is in part treatment-dependent. However, older age and the presence of the Philadelphia (Ph) chromosome have been universally identified as markers of poor prognosis. Post-remission therapy for Ph chromosome positive ALL is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44489?source=see_link\">",
"     \"Induction therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, an analysis of more than 400 adults with ALL treated on prospective clinical trials that principally used chemotherapy without transplantation as post-remission therapy identified the following clinical and biologic features, which correlate with favorable long-term outcome: age &lt;30 years, white blood cell count",
"    <span class=\"nowrap\">",
"     &lt;30,000/microL",
"    </span>",
"    at diagnosis, the presence of a mediastinal mass, T cell immunophenotype (with or without myeloid markers), and the absence of the Ph chromosome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with no adverse features had a 91 percent estimated probability of survival at three years (95 percent confidence interval, 66 to 98 percent).",
"     </li>",
"     <li>",
"      Survival was a continuous function of age. The three-year survival rates were 66 and 36 percent for patients less than 30 and those 30 to 59 years old, respectively.",
"     </li>",
"     <li>",
"      The estimated three-year survival rates of patients with one, two, or three unfavorable characteristics (as defined above) were 64, 49, and 21 percent, respectively. None of the patients with four adverse risk factors survived more than three years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies in children and adults with ALL have also identified the time to initial complete remission (CR) as a marker of prognosis; those patients who achieve CR by day 14 have superior survival rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/7-12\">",
"     7-12",
"    </a>",
"    ]. As an example, a controlled trial of 2090 children with ALL randomly assigned to receive either standard or intensified therapy reported that the blast percentage on day eight of therapy was a significant predictor of prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/7\">",
"     7",
"    </a>",
"    ]. Patients with 25 percent or fewer bone marrow blasts on day eight had higher rates of progression-free survival at three years (eg, 74 versus 62 percent, respectively).",
"   </p>",
"   <p>",
"    Presence of minimal residual disease using flow cytometry can also predict for inferior outcomes. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/56/31625?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical use of minimal residual disease detection in acute lymphoblastic leukemia\", section on 'MRD in adults'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with Ph+ ALL, t(4;11), t(8;14), complex karyotype, or low",
"    <span class=\"nowrap\">",
"     hypodiploid/near",
"    </span>",
"    triploidy have inferior rates of event-free and overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/13\">",
"     13",
"    </a>",
"    ]. In contrast, patients with high hyperdiploidy, del(9p), or a translocation involving chromosome band 14q11-13 had a significantly improved outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. A small percentage of patients with adult ALL, almost all under 35 years of age, have t(12;21) and a favorable outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CONSOLIDATION AND INTENSIFICATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63940798\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, the three main options for consolidation therapy (in order of increasing intensity) are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Consolidation chemotherapy &mdash; Nonmyeloablative chemotherapy has a low treatment-related mortality rate (less than 5 percent). Common major side effects are generally short-term and include pancytopenia, infection, hepatic impairment, and neuropathy.",
"     </li>",
"     <li>",
"      Autologous hematopoietic cell transplantation (HCT) &mdash; Autologous HCT allows the use of myeloablative chemotherapy and is not associated with graft-versus-host disease (GVHD), but does not provide the graft-versus-leukemia (GVL) effect seen with allogeneic HCT. Treatment-related morbidity and mortality are relatively low (&le;6 percent). Prospective randomized trials have reported that event-free and overall survival rates with autologous HCT are either similar or inferior to those obtained with consolidation chemotherapy.",
"     </li>",
"     <li>",
"      Allogeneic HCT &mdash; Allogeneic HCT targets cancer cells both by administering intensive and sometimes myeloablative chemotherapy and by harnessing a GVL effect. Treatment-related mortality is high on average (approximately 20 percent), but varies in individuals according to patient-related transplantation risk factors (eg, age, comorbid conditions). In addition, allogeneic HCT can result in significant morbidity associated with GVHD, chronic cytopenias, second malignancies, cataracts, and sterility. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/59/25529?source=see_link\">",
"       \"Quality of life following hematopoietic cell transplantation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is great variability in practice and it remains controversial how intensive post-remission therapy should be, but most clinicians use a risk-adapted treatment approach where patients with disease at high risk for relapse are treated with more aggressive therapy (eg, allogeneic HCT) than patients at standard risk for relapse. This approach minimizes exposure to potentially toxic therapies in patients expected to respond well to conventional chemotherapy while providing maximum antitumor activity for patients with more difficult-to-treat disease.",
"   </p>",
"   <p>",
"    The following sections describe our approach to the treatment of standard and high risk disease. Patients with Philadelphia chromosome positive ALL require specialized therapy and this is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44489?source=see_link\">",
"     \"Induction therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Standard risk disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no clear consensus regarding the optimal consolidation therapy for patients with standard risk ALL. Consolidation chemotherapy produces four-year survival rates of 40 to 60 percent. Common major side effects include pancytopenia, infection, liver toxicity, and neuropathy. The majority of deaths are due to relapsed disease and long-term complications from therapy are rare. Alternatively, allogeneic HCT results in a lower relapse rate, but higher rates of treatment-related mortality and morbidity resulting in similar rates of long-term survival. In contrast, autologous HCT does not appear to improve on the results seen with consolidation chemotherapy or allogeneic HCT in this population.",
"   </p>",
"   <p>",
"    There have been no randomized trials directly comparing consolidation chemotherapy with allogeneic HCT. Other analyses have had mixed results with some suggesting that allogeneic HCT may result in higher long-term overall survival and others reporting that it does not. Given this uncertainty, all patients should be encouraged to participate in clinical trials. We offer the following guidance for the treatment of patients who are either not candidates for clinical trials or choose not to participate.",
"   </p>",
"   <p>",
"    For most patients with standard risk ALL in CR1, we suggest the use of consolidation chemotherapy rather than either allogeneic or autologous HCT. This preference places a relatively high value on avoiding the higher short-term mortality and long-term morbidity associated with HCT and a low value on the potential, but uncertain, ability of the more intensive transplant therapy to eliminate residual disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consolidation chemotherapy for ALL consists of a variety of chemotherapy agents with different mechanisms of action administered in combinations over several courses at short intervals that span a total of approximately seven months. The individual drugs used vary by protocol, but typically include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , 6-mercaptopurine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef67471 \" href=\"mobipreview.htm?12/56/13198\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef81231 \" href=\"mobipreview.htm?30/12/30927\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef54375 \" href=\"mobipreview.htm?22/26/22959\">",
"     table 3",
"    </a>",
"    ). Central nervous system prophylaxis with either intrathecal chemotherapy or radiation therapy is incorporated as well. The goal is to deliver high doses of these agents without causing severe cytopenias that lead to treatment delays.",
"   </p>",
"   <p>",
"    These regimens have evolved empirically with few of the individual components tested rigorously in randomized trials. Thus, it is difficult to analyze critically the absolute contribution of each drug or dose schedule to the ultimate outcome. Numerous nonrandomized trials have attempted to answer these questions, but multiple alterations in study design between sequential trials have made it difficult to assess the exact merit of each modification.",
"   </p>",
"   <p>",
"    Several nonrandomized studies strongly suggest a benefit from intensive multiagent postremission chemotherapy. In contrast, prospective studies evaluating even more intensive chemotherapy regimens have not demonstrated improved outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/4,5,16-20\">",
"     4,5,16-20",
"    </a>",
"    ]. The following are examples of the most commonly used chemotherapy regimens for ALL in adults:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cancer and Leukemia Group B (CALGB study 9111) ALL regimen (",
"      <a class=\"graphic graphic_table graphicRef67471 \" href=\"mobipreview.htm?12/56/13198\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/14,21\">",
"       14,21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Standard or augmented Berlin-Frankfurt-Munster (BFM) (",
"      <a class=\"graphic graphic_table graphicRef81231 \" href=\"mobipreview.htm?30/12/30927\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hyperfractionated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (Hyper-CVAD) alternating with high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef50617 \" href=\"mobipreview.htm?19/26/19886\">",
"       table 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/23\">",
"       23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      French GRAAL-2003 regimen for younger adults (",
"      <a class=\"graphic graphic_table graphicRef54375 \" href=\"mobipreview.htm?22/26/22959\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    None of these regimens has been directly compared in a prospective randomized trial. As such, there is no single best regimen for post-remission therapy. In general, the consolidation chemotherapy regimen should be consistent with the induction regimen that was chosen at the time of diagnosis. This choice should be made based upon the physician's comfort with administration and patient characteristics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23642?source=see_link&amp;anchor=H3#H3\">",
"     \"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\", section on 'Chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Chemotherapy versus allogeneic transplant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consolidation chemotherapy has not been directly compared with allogeneic HCT in randomized trials. Instead, investigators have relied on a \"genetic randomization\" in which patients are assigned to treatment with or without allogeneic HCT based upon the presence or absence of an HLA-matched sibling donor. Patients without an HLA-matched sibling are assigned to treatment with either chemotherapy alone or autologous HCT, depending upon the trial design. Results are then evaluated by an intention-to-treat analysis for \"donor\" and \"no donor\" (available) treatment groups. As with randomized trials, not all patients in the \"donor\" group ultimately receive an allogeneic HCT, but they would still be included in the \"donor\" group for the statistical analysis.",
"   </p>",
"   <p>",
"    There is clearly more treatment-related mortality as well as later morbidity after allogeneic HCT than after chemotherapy alone. However, the relapse rate is reduced by allogeneic transplantation. Younger age (&lt;35 years), better transplantation methods, and availability of an optimal donor may favor allogeneic HCT in CR1. This is discussed in more detail separately. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Allogeneic transplant versus chemotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Chemotherapy versus autologous transplant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autologous HCT has been used experimentally for patients with ALL who are not candidates for allogeneic HCT. It is associated with fewer treatment-related complications, largely due to the lack of graft-versus-host disease (GVHD). In addition, developments in technology and supportive care have made autologous HCT available for larger numbers of patients, including older adults. However, autologous HCT does not have a graft-versus-leukemia (GVL) effect, which is a key component of the transplantation process. As described above, prospective randomized trials have reported that event-free and overall survival rates with auto-HCT are either similar or inferior to those obtained with consolidation chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/25-32\">",
"     25-32",
"    </a>",
"    ] (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Chemotherapy versus allogeneic transplant'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As an example, in the French LALA-87 trial described above, patients 15 to 40 years of age who lacked an HLA-identical sibling, and those 40 to 50 years of age and still in CR1 after two courses of consolidation chemotherapy, were randomly assigned to auto-HCT or to maintenance chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. There were no differences in overall survival (34 versus 29 percent in the chemotherapy arm) or in survival in either the high-risk (16 versus 11 percent) or standard risk (49 versus 40 percent) subgroups.",
"   </p>",
"   <p>",
"    The main cause for failure after auto-HCT for ALL is a high relapse rate. The factors implicated in this process include the inefficiency of the conditioning regimen in eradicating leukemia, the lack of",
"    <span class=\"nowrap\">",
"     GVHD/GVL,",
"    </span>",
"    and contamination of the stem cell graft by leukemic cells. Data indicate that the autograft can be the source of recurrent ALL cells in some cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/33\">",
"     33",
"    </a>",
"    ]. However, it is equally likely that many relapses arise from residual disease in the subject, not from graft contamination. This may be the main reason why purging bone marrow in vitro has no detectable impact on relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Maintenance chemotherapy has not commonly been used after auto-HCT, although one study reported a probability of survival of 53 percent at 10 years when auto-HCT was followed by two years of maintenance chemotherapy for adults in CR1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/32\">",
"     32",
"    </a>",
"    ]. On the other hand, a randomized trial evaluating interleukin (IL)-2 after auto-HCT showed no benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive care is a critical component to the treatment of patients with acute leukemia. This includes the management of cytopenias, infections, tumor lysis, and other complications that accompany the treatment of acute leukemia. These are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=see_link&amp;anchor=H14#H14\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'Supportive care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     High risk disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with high risk disease, as defined above, do poorly when treated with consolidation chemotherapy alone after attainment of a complete remission (CR1); rates of 10-year overall survival with this approach are approximately 10 percent. In contrast, treatment with allogeneic hematopoietic cell transplantation (HCT) provides an additional graft-versus-leukemia (GVL) effect together with myeloablative chemotherapy, resulting in superior survival rates of approximately 45 percent at 10 years.",
"   </p>",
"   <p>",
"    For young patients with high-risk ALL in CR1 who have an HLA-matched donor, we recommend allogeneic HCT rather than consolidation chemotherapy or autologous HCT. Unfortunately, many patients achieving a CR are excluded from HCT due to early relapse, comorbid medical conditions, lack of insurance, or lack of a suitable HLA-matched donor. For patients with high-risk ALL in CR1 who are not candidates for allogeneic HCT, we suggest consolidation chemotherapy rather than autologous HCT. Alternatively, these patients may be considered for reduced-intensity allogeneic HCT as part of a clinical trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with Philadelphia chromosome positive ALL require specialized therapy; this is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44489?source=see_link\">",
"     \"Induction therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Allogeneic transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;When used for young adults with high risk disease, allogeneic HCT results in 10-year overall survival rates of approximately 45 percent. Short-term morbidities include pancytopenia, infections, mucositis, hepatic disease, and psychosocial effects. Long-term complications include graft-versus-host disease (GVHD), chronic immune suppression, cytopenias, cataracts, lung dysfunction, secondary malignancies, and infertility. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34664?source=see_link\">",
"     \"Hematopoietic support after hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/59/25529?source=see_link\">",
"     \"Quality of life following hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29306?source=see_link\">",
"     \"Supportive care after hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/44/35530?source=see_link\">",
"     \"The approach to hematopoietic cell transplantation survivorship\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A discussion on specifics related to allogeneic transplantation in adults with ALL including donor selection, preparative chemoradiotherapy, and the graft-versus-leukemia effect is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/11/9400?source=see_link\">",
"     \"General principles of hematopoietic cell transplantation for acute lymphoblastic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Outcomes with allogeneic HCT compared with chemotherapy are presented in the following section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Allogeneic transplant versus chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consolidation chemotherapy has not been directly compared with allogeneic HCT in randomized trials. Instead, investigators have relied on a \"genetic randomization\" in which patients are assigned to treatment with or without allogeneic HCT based upon the presence or absence of an HLA-matched sibling donor. Patients without an HLA-matched sibling are assigned to treatment with either chemotherapy alone or autologous HCT, depending upon the trial design. Results are then evaluated by an intention-to-treat analysis for \"donor\" and \"no donor\" (available) treatment groups. As with randomized trials, not all patients in the \"donor\" group ultimately receive an allogeneic HCT, but they would still be included in the \"donor\" group for the statistical analysis. Similarly, some patients in the &ldquo;no donor&rdquo; group will go on to receive a matched unrelated allogeneic HCT, but they would still be included in the &ldquo;no donor&rdquo; group for statistical analysis.",
"   </p>",
"   <p>",
"    These donor versus no donor comparisons have had conflicting results. The following are examples of some of the largest donor versus no donor comparisons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The French LALA-87 trial investigated the use of allo-HCT, auto-HCT, or consolidation chemotherapy for 436 patients with ALL in first complete remission (CR1) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. Patients aged 15 to 40 years underwent HLA-typing and 116 had an HLA-identical sibling, 98 of whom underwent a matched sibling HCT. Those without an HLA-identical sibling and patients 40 to 50 years old were randomly assigned treatment with either auto HCT (95 patients) or chemotherapy (96 patients). All patients over 50 years were treated with chemotherapy alone (58 patients). In a donor versus no donor comparison of the transplant-eligible group, there was no significant difference in median disease-free survival (24 versus 22 months) or overall survival (51 versus 30 months) for those patients with or without sibling donors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/36\">",
"       36",
"      </a>",
"      ]. On subgroup analysis of the 161 patients with standard risk ALL, there was no significant difference in median survival (not reached versus 56 months) or disease-free survival (27 versus 30 months) for those who did or did not have a matched sibling. On subset analysis, however, allo-HCT was associated with a significant survival advantage (44 versus 11 percent in controls) in the high-risk patients defined as Ph+ ALL, null or undifferentiated immunophenotype, or common ALL with either age greater than 35 years, WBC",
"      <span class=\"nowrap\">",
"       &gt;30,000/microL,",
"      </span>",
"      or time to achieve CR greater than four weeks.",
"     </li>",
"     <li>",
"      An international",
"      <span class=\"nowrap\">",
"       (MRC/ECOG)",
"      </span>",
"      ALL trial was a collaborative prospective, randomized trial that compared these same three consolidation strategies in 1484 adults with ALL in CR1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. Patients younger than 55 years who had an HLA-matched sibling donor were assigned to allo-HCT. Other patients were randomly assigned to auto-HCT or chemotherapy for 2.5 years. At a median follow-up of five years, the following results were reported:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Evaluation of the 1031 patients who were younger than 55 years found that patients with a donor had a significantly higher five-year overall survival rate (53 versus 45 percent). On a subset analysis of the 562 standard risk patients, patients with a donor had a significantly lower relapse rate at 10 years (24 versus 49 percent), a higher non-relapse mortality rate at two years (19.5 versus 6.9 percent), and a higher overall survival rate (62 versus 52 percent) when compared with those without a donor.",
"     </li>",
"     <li>",
"      Patients randomized to receive chemotherapy had significantly improved rates of five-year event-free (41 versus 32 percent) and overall (46 versus 37 percent) survival when compared with those who were randomized to autologous HCT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A Dutch-Belgian prospective trial that included 288 patients younger than age 55 with standard risk ALL in CR1 assigned therapy based upon the availability of a sibling donor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/37\">",
"       37",
"      </a>",
"      ]. Patients with a donor were assigned allogeneic HCT while those without a donor were assigned autologous HCT. Patients who had a donor demonstrated a significantly lower incidence of relapse (24 versus 55 percent), superior disease-free survival (60 versus 42 percent), and improved overall survival (69 versus 49 percent) at five years.",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       MRC/ECOG",
"      </span>",
"      ALL trial was a collaborative prospective, randomized trial that compared these same three consolidation strategies for adults with ALL in CR1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/27\">",
"       27",
"      </a>",
"      ]. Patients younger than 55 years who had an HLA-matched sibling donor were assigned to allo-HCT. Other patients were randomly assigned to auto-HCT or chemotherapy for 2.5 years. At a median follow-up of five years, patients who had a sibling donor had a significantly higher five-year overall survival rate (53 versus 45 percent). However, this difference did not retain its significance in a subset analysis of the high risk patients without the Ph chromosome (41 versus 35 percent). This was likely due to a higher two-year non-relapse mortality rate among the high-risk patients with a donor when compared with the standard-risk patients with a donor (36 versus 20 percent). Patients randomized to receive chemotherapy had significantly improved rates of five-year event-free (41 versus 32 percent) and overall (46 versus 37 percent) survival when compared with those who were randomized to autologous HCT.",
"     </li>",
"     <li>",
"      A 2013 meta-analysis included individualized data from 2962 patients with Philadelphia chromosome negative ALL in CR1 enrolled in 13 trials with &ldquo;genetic randomization&rdquo; to allogeneic HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/38\">",
"       38",
"      </a>",
"      ]. The identification of a matched sibling donor was associated with the following outcomes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fewer relapses (odds ratio [OR] 0.58; 95% CI 0.52-0.65).",
"     </li>",
"     <li>",
"      Higher treatment related mortality (OR 2.36; 95% CI",
"      <span class=\"nowrap\">",
"       1/94-2.86).",
"      </span>",
"     </li>",
"     <li>",
"      Superior overall survival (hazard ratio 0.87; 95% CI 0.79-0.96).",
"     </li>",
"     <li>",
"      High risk ALL was defined by a white blood cell count at diagnosis",
"      <span class=\"nowrap\">",
"       &gt;30,000/microL",
"      </span>",
"      in B-ALL or",
"      <span class=\"nowrap\">",
"       &gt;100,000/microL",
"      </span>",
"      in T-ALL. For patients classified as having high risk disease, overall survival was not significantly improved for those with a matched sibling (hazard ratio 0.90; 95% CI 0.71-1.14).",
"     </li>",
"     <li>",
"      The survival benefit was most apparent in patients &lt;35 years (HR 0.79; 95% CI 0.67-0.94), and was not demonstrated in patients &ge;35 years (HR 1.01; 95% CI 0.81-1.26). This appeared to be due to a decreased TRM in patients &lt;35 years (32 versus 19 percent in those with donors).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is clearly more treatment-related mortality as well as later morbidity after allogeneic HCT than after chemotherapy alone. However, the relapse rate is reduced by allogeneic transplantation. Younger age (&lt;35 years), better transplantation methods, and availability of an optimal donor may favor allogeneic HCT in CR1.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1935499\">",
"    <span class=\"h3\">",
"     Treatment of younger adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective data supporting the use of regimens developed by pediatric cooperative groups that emphasize more aggressive central nervous system prophylaxis, use of anti-metabolites, and repeated administration of non-myelosuppressive agents including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    and asparaginase have led to ongoing studies assessing such approaches in previously untreated patient with ALL up to age 40 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31850?source=see_link\">",
"     \"Overview of the treatment of acute lymphoblastic leukemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MAINTENANCE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Remission maintenance therapy is a standard component of the management of ALL and is given for two to three years after consolidation therapy. In general, maintenance therapy is not used after allogeneic HCT, although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    is sometimes offered after allogeneic HCT as maintenance to patients who had Philadelphia chromosome positive disease. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44489?source=see_link\">",
"     \"Induction therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most standard maintenance regimens consist of daily 6-mercaptopurine, weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and monthly pulses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (ie, POMP). As yet, the efficacy of maintenance therapy in adults has not been assessed via a randomized trial. Trials omitting or shortening maintenance therapy appear to produce inferior results than those obtained with maintenance. In addition, longer maintenance may not improve on results seen with two years of maintenance. The optimal duration and timing for maintenance treatment is unknown.",
"   </p>",
"   <p>",
"    Two prospective studies that omitted maintenance treatment following the completion of consolidation therapy are notable for short disease-free survival times when compared with historical controls:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In CALGB study 8513, which completed treatment after 29 weeks, the median remission duration was only 11 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/39\">",
"       39",
"      </a>",
"      ]. This was markedly shorter than the 21-month remission duration seen in the earlier CALGB study 8011 in which three years of therapy were administered [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/16\">",
"       16",
"      </a>",
"      ]. Median survival was also inferior in the group that received shorter therapy (19 versus 30 months).",
"     </li>",
"     <li>",
"      ECOG studies 2483 and 3486 treated a total of 336 patients with induction followed by intensive 12-month consolidation, but no maintenance therapy with median disease-free survival of only nine and 11 months, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is unclear if the poor results seen in these studies of shortened therapy are due to inadequate initial induction and consolidation treatment or to the lack of prolonged maintenance therapy.",
"   </p>",
"   <p>",
"    A meta-analysis of 42 trials that included 12,000 children with ALL who received longer versus shorter maintenance therapy reported that there was no evidence that five years of maintenance was better than three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/15/39161/abstract/40\">",
"     40",
"    </a>",
"    ]. However, when compared with those who received two years of maintenance, patients given three years of maintenance had lower combined rates of relapse or death (23 versus 28 percent).",
"   </p>",
"   <p>",
"    For patients who are still in complete remission after completing consolidation chemotherapy, we recommend two to three years of maintenance chemotherapy. The most commonly used regimen is POMP administered for three years.",
"   </p>",
"   <p>",
"    During maintenance therapy, patients remain at risk for infection. Fever in patients who are receiving chemotherapy must be evaluated and treated aggressively, especially if the patient is either neutropenic or has a central venous access device.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    prophylaxis may be used to prevent Pneumocystis carinii (P. jirovecii) pneumonia. Patients and their household contacts should not be given live-virus immunization while receiving chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/52/40778?source=see_link\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9289?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Prophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/37/30296?source=see_link&amp;anchor=H2#H2\">",
"     \"Immunizations in patients with cancer\", section on 'General approach'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/37/30296?source=see_link&amp;anchor=H13#H13\">",
"     \"Immunizations in patients with cancer\", section on 'Live organism vaccines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If there is unexpectedly severe or prolonged myelosuppression in patients taking 6-mercaptopurine, the medication should be stopped and an analysis obtained for thiopurine methyltransferase activity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/32/22026?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of pharmacogenomics\", section on 'Thiopurine methyltransferase'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     FOLLOW UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the completion of maintenance therapy, patients in complete clinical remission usually have a bone marrow aspiration and biopsy repeated periodically to assess for residual or relapsed disease. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/15/21753?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of relapsed or refractory acute lymphoblastic leukemia in adults\", section on 'Evaluation for relapse or resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-term survivors of ALL can develop late adverse effects related to treatment including central nervous system impairment, cardiotoxicity, infertility, and an increased incidence of secondary cancers, as well as an overall decreased health status due to such factors as neurocognitive dysfunction, depression, fatigue, and anxiety. The occurrence of specific complications depends upon the patient's age and the type and intensity of therapy with which they were treated. These long-term side effects are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40649?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of the outcome of acute lymphoblastic leukemia in children\", section on 'Late effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/44/35530?source=see_link\">",
"     \"The approach to hematopoietic cell transplantation survivorship\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/34/17955?source=see_link\">",
"       \"Patient information: Acute lymphoblastic leukemia (ALL) treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Over 80 percent of adult patients with newly diagnosed acute lymphoblastic leukemia (ALL) will attain a first complete remission (CR1) with intensive induction chemotherapy. However, without additional cytotoxic therapy, virtually all of these patients will relapse within a few weeks or months. In contrast, patients who receive post-remission therapy may expect five-year survival rates up to 60 percent in young and middle-age adults with standard risk disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ALL is a heterogeneous disease and outcomes vary by clinical, cytogenetic, and molecular features. Patients should be evaluated at diagnosis to determine if they have standard or high risk disease as this will affect the choice of post-remission therapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk stratification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no standard post-remission therapy for patients with ALL. Most clinicians use a risk-adapted treatment approach where patients with disease at high risk for relapse are treated with more aggressive therapy (eg, allogeneic hematopoietic cell transplantation) than patients at standard risk for relapse. (See",
"      <a class=\"local\" href=\"#H63940798\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with standard risk ALL in CR1, we suggest the use of consolidation and maintenance chemotherapy rather than either allogeneic or autologous HCT (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). This preference places a relatively high value on avoiding the higher short-term mortality and long-term morbidity associated with HCT and a low value on the potential, but uncertain, ability of the more intensive transplant therapy to eliminate residual disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Standard risk disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For young patients with high-risk ALL in CR1 who have an HLA-matched donor, we recommend allogeneic HCT rather than consolidation chemotherapy or autologous HCT (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For patients with high-risk ALL in CR1 who are not candidates for allogeneic HCT, we suggest consolidation chemotherapy rather than autologous HCT (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Patients with Philadelphia chromosome positive ALL require specialized therapy and this is discussed in more detail separately. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'High risk disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44489?source=see_link\">",
"       \"Induction therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who are still in CR1 after completing consolidation chemotherapy, we recommend two to three years of maintenance chemotherapy rather than observation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The most commonly used regimen is daily 6-mercaptopurine given in the evening, weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , and monthly pulses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (ie, POMP) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      administered for three years. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients are followed after the completion of maintenance therapy for signs and symptoms of relapsed disease or late effects of treatment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/15/21753?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment of relapsed or refractory acute lymphoblastic leukemia in adults\", section on 'Evaluation for relapse or resistance'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40649?source=see_link&amp;anchor=H7#H7\">",
"       \"Overview of the outcome of acute lymphoblastic leukemia in children\", section on 'Late effects'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/1\">",
"      Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/2\">",
"      Burmeister T, G&ouml;kbuget N, Schwartz S, et al. Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia. Haematologica 2010; 95:241.",
"     </a>",
"    </li>",
"    <li>",
"     Larson RA, Dodge RK, Bloomfield CD, Schiffer CA. Treatment of biologically determined subsets of acute lymphoblastic leukemia in adults: Cancer and Leukemia Group B studies. In: Acute Leukemias VI: Prognostic factors and treatment strategies, Buchner T, Hiddeman W, Wormann B, et al. (Eds), Springer-Verlag, Berlin 1997. p.677.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/4\">",
"      Linker CA, Levitt LJ, O'Donnell M, et al. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood 1991; 78:2814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/5\">",
"      Hoelzer D, Thiel E, L&ouml;ffler H, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988; 71:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/6\">",
"      Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005; 106:3760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/7\">",
"      Hann I, Vora A, Harrison G, et al. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. Br J Haematol 2001; 113:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/8\">",
"      Ribera JM, Ortega JJ, Oriol A, et al. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial. Haematologica 2002; 87:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/9\">",
"      Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-M&uuml;nster. Leukemia 2000; 14:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/10\">",
"      Visser JH, Wessels G, Hesseling PB, et al. Prognostic value of day 14 blast percentage and the absolute blast index in bone marrow of children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 2001; 18:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/11\">",
"      Laughton SJ, Ashton LJ, Kwan E, et al. Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in children with acute lymphoblastic leukemia. J Clin Oncol 2005; 23:2264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/12\">",
"      Roy A, Bradburn M, Moorman AV, et al. Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial. Br J Haematol 2005; 129:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/13\">",
"      Frassoni F, Labopin M, Gluckman E, et al. Are patients with acute leukaemia, alive and well 2 years post bone marrow transplantation cured? A European survey. Acute Leukaemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). Leukemia 1994; 8:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/14\">",
"      Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 1995; 85:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/15\">",
"      Laport GF, Larson RA. Treatment of adult acute lymphoblastic leukemia. Semin Oncol 1997; 24:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/16\">",
"      Ellison RR, Mick R, Cuttner J, et al. The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B. J Clin Oncol 1991; 9:2002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/17\">",
"      Cassileth PA, Andersen JW, Bennett JM, et al. Adult acute lymphocytic leukemia: the Eastern Cooperative Oncology Group experience. Leukemia 1992; 6 Suppl 2:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/18\">",
"      Stryckmans P, De Witte T, Marie JP, et al. Therapy of adult ALL: overview of 2 successive EORTC studies: (ALL-2 &amp; ALL-3). The EORTC Leukemia Cooperative Study Group. Leukemia 1992; 6 Suppl 2:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/19\">",
"      Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004; 22:4075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/20\">",
"      Thomas D, O'Brien S, Faderl S, et al. Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen. Cancer 2010; 116:4580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/21\">",
"      Larson RA, Dodge RK, Linker CA, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 1998; 92:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/22\">",
"      Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood 2008; 112:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/23\">",
"      Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/24\">",
"      Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009; 27:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/25\">",
"      Thiebaut A, Vernant JP, Degos L, et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am 2000; 14:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/26\">",
"      Fi&egrave;re D, Lepage E, Sebban C, et al. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia. J Clin Oncol 1993; 11:1990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/27\">",
"      Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008; 111:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/28\">",
"      Fielding AK, Goldstone AH. Allogeneic haematopoietic stem cell transplant in Philadelphia-positive acute lymphoblastic leukaemia. Bone Marrow Transplant 2008; 41:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/29\">",
"      Kantarjian HM, Walters RS, Keating MJ, et al. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol 1990; 8:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/30\">",
"      Carey PJ, Proctor SJ, Taylor P, Hamilton PJ. Autologous bone marrow transplantation for high-grade lymphoid malignancy using melphalan/irradiation conditioning without marrow purging or cryopreservation. The Northern Regional Bone Marrow Transplant Group. Blood 1991; 77:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/31\">",
"      Attal M, Blaise D, Marit G, et al. Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group. Blood 1995; 86:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/32\">",
"      Powles R, Sirohi B, Treleaven J, et al. The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia. Blood 2002; 100:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/33\">",
"      Brenner MK, Rill DR, Moen RC, et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/34\">",
"      Labopin M, Gorin NC. Autologous bone marrow transplantation in 2502 patients with acute leukemia in Europe: a retrospective study. Leukemia 1992; 6 Suppl 4:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/35\">",
"      Bachanova V, Verneris MR, DeFor T, et al. Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood 2009; 113:2902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/36\">",
"      Sebban C, Lepage E, Vernant JP, et al. Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia. J Clin Oncol 1994; 12:2580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/37\">",
"      Cornelissen JJ, van der Holt B, Verhoef GE, et al. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. Blood 2009; 113:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/38\">",
"      Gupta V, Richards S, Rowe J, Acute Leukemia Stem Cell Transplantation Trialists' Collaborative Group. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. Blood 2013; 121:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/39\">",
"      Cuttner J, Mick R, Budman DR, et al. Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB Study. Leukemia 1991; 5:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/15/39161/abstract/40\">",
"      Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children. Childhood ALL Collaborative Group. Lancet 1996; 347:1783.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4503 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.32.226.102-B08792FACF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_15_39161=[""].join("\n");
var outline_f38_15_39161=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK STRATIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CONSOLIDATION AND INTENSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63940798\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Standard risk disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Chemotherapy versus allogeneic transplant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Chemotherapy versus autologous transplant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      High risk disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Allogeneic transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Allogeneic transplant versus chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1935499\">",
"      - Treatment of younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MAINTENANCE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      FOLLOW UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4503\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4503|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/56/13198\" title=\"table 1\">",
"      CALGB regimen ALL adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/12/30927\" title=\"table 2\">",
"      BFM regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/26/22959\" title=\"table 3\">",
"      GRAALL 2003 regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/26/19886\" title=\"table 4\">",
"      Modified Hyper CVAD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26007?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of precursor B cell acute lymphoblastic leukemia/lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/20/30023?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/56/31625?source=related_link\">",
"      Clinical use of minimal residual disease detection in acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/25/22938?source=related_link\">",
"      Cytogenetics in acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/32/15880?source=related_link\">",
"      Detection of minimal residual disease in acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/11/9400?source=related_link\">",
"      General principles of hematopoietic cell transplantation for acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34664?source=related_link\">",
"      Hematopoietic support after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/37/30296?source=related_link\">",
"      Immunizations in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23642?source=related_link\">",
"      Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44489?source=related_link\">",
"      Induction therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=related_link\">",
"      Induction therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/32/22026?source=related_link\">",
"      Overview of pharmacogenomics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40649?source=related_link\">",
"      Overview of the outcome of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31850?source=related_link\">",
"      Overview of the treatment of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/34/17955?source=related_link\">",
"      Patient information: Acute lymphoblastic leukemia (ALL) treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/59/25529?source=related_link\">",
"      Quality of life following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29306?source=related_link\">",
"      Supportive care after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/44/35530?source=related_link\">",
"      The approach to hematopoietic cell transplantation survivorship",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/52/40778?source=related_link\">",
"      Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/15/21753?source=related_link\">",
"      Treatment of relapsed or refractory acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_15_39162="Child asthma action plan";
var content_f38_15_39162=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71958&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71958&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 628px\">",
"   <div class=\"ttl\">",
"    Child asthma action plan",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 608px; height: 789px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_15_39162=[""].join("\n");
var outline_f38_15_39162=null;
var title_f38_15_39163="Testicular tumors PI";
var content_f38_15_39163=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F62949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F62949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of testicular tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Germ cell tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Seminoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Seminoma with syncytiotrophoblastic cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Spermatocytic seminoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Spermatocytic seminoma with sarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Nonseminomatous germ cell tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Embryonal carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Teratoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Dermoid cyst",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Monodermal teratoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Teratoma with somatic type malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Trophoblastic tumors (choriocarcinoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Yolk sac tumor (endodermal sinus tumor)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mixed germ cell tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Sex cord-stromal tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sertoli cell tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leydig cell tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granulosa cell tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mixed types (eg, Sertoli-Leydig cell tumor)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unclassified",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Tumours of the Urinary System and Male Genital Organs. Eble, JN, Sauter, G, Epstein, JI, Sesterhenn, IA (Eds). In: World Health Organization Classification of Tumours. Lyon 2004.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_15_39163=[""].join("\n");
var outline_f38_15_39163=null;
var title_f38_15_39164="Features of JIA subtypes";
var content_f38_15_39164=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F56224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F56224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Features of three of the major subtypes of juvenile idiopathic arthritis (JIA)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Systemic onset JIA",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pauciarticular onset JIA",
"       </td>",
"       <td class=\"subtitle1\">",
"        Polyarticular onset JIA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Percent of JIA patients",
"       </td>",
"       <td>",
"        10 to 15",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        30 to 40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sex",
"       </td>",
"       <td>",
"        F = M",
"       </td>",
"       <td>",
"        F &gt; M",
"       </td>",
"       <td>",
"        F &gt; M",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age",
"       </td>",
"       <td>",
"        any &lt;17 years",
"       </td>",
"       <td>",
"        peak 2 to 3 years, rare &gt;10",
"       </td>",
"       <td>",
"        peaks 2 to 5, 10 to 14 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Joints",
"       </td>",
"       <td>",
"        any",
"       </td>",
"       <td>",
"        large joints, but rarely hips",
"       </td>",
"       <td>",
"        any, rare to start in hip",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever, rash, lymphadenopathy, hepatosplenomegaly",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"       <td>",
"        no",
"       </td>",
"       <td>",
"        no",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uveitis",
"       </td>",
"       <td>",
"        rare",
"       </td>",
"       <td>",
"        20 percent, esp ANA +",
"       </td>",
"       <td>",
"        less frequent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\">",
"        Laboratory abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Leukocytosis",
"       </td>",
"       <td class=\"sublist_other\">",
"        marked",
"       </td>",
"       <td class=\"sublist_other\">",
"        no",
"       </td>",
"       <td class=\"sublist_other\">",
"        no",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Anemia",
"       </td>",
"       <td class=\"sublist_other\">",
"        marked",
"       </td>",
"       <td class=\"sublist_other\">",
"        no",
"       </td>",
"       <td class=\"sublist_other\">",
"        mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Elevated ESR",
"       </td>",
"       <td class=\"sublist_other\">",
"        marked",
"       </td>",
"       <td class=\"sublist_other\">",
"        mild",
"       </td>",
"       <td class=\"sublist_other\">",
"        mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - ANA",
"       </td>",
"       <td class=\"sublist_other\">",
"        absent",
"       </td>",
"       <td class=\"sublist_other\">",
"        low titer common",
"       </td>",
"       <td class=\"sublist_other\">",
"        low titer common in younger",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Rheumatoid factor",
"       </td>",
"       <td class=\"sublist_other\">",
"        rare",
"       </td>",
"       <td class=\"sublist_other\">",
"        absent",
"       </td>",
"       <td class=\"sublist_other\">",
"        10 to 20 percent in those &gt;10 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Destructive arthritis",
"       </td>",
"       <td>",
"        &gt;50 percent",
"       </td>",
"       <td>",
"        rare",
"       </td>",
"       <td>",
"        &gt;50 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disease modifying drugs",
"       </td>",
"       <td>",
"        commonly used",
"       </td>",
"       <td>",
"        rarely used",
"       </td>",
"       <td>",
"        commonly used",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_15_39164=[""].join("\n");
var outline_f38_15_39164=null;
var title_f38_15_39165="Drug interactions with NMBAs";
var content_f38_15_39165=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potential drug interactions with NMBAs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Enhance the neuromuscular effect of NMBAs",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1_start\">",
"           Acetylcholinesterase inhibitors*",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Donepezil",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Galantamine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Echothiophate iodine*",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Neostigmine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Physostigmine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Pyridostigmine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Rivastigmine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Tacrine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1_start\">",
"           Antibiotics",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Aminoglycosides",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist2\">",
"           Amikacin",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist2\">",
"           Gentamicin",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist2\">",
"           Kanamycin",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist2\">",
"           Neomycin",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist2\">",
"           Streptomycin",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist2\">",
"           Tobramycin",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Amphotericin B",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Colistin",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Lincosamides",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist2\">",
"           Clindamycin",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist2\">",
"           Lincomycin",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Polymyxin B",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1_start\">",
"           Calcium channel blockers&bull;",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Amlodipine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Bepridil&Delta;",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Clevidipine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Diltiazem",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Felodipine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Isradipine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Nicardipine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Nifedipine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Nilvadipine&Delta;",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Nimodipine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Nisoldipine, nitrendipine&Delta;",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Verapamil",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Cyclophosphamide*",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1_start\">",
"           Loop diuretics (low doses)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Bumetanide",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Ethacrynic acid",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Furosemide",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Torsemide",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Magnesium Salts",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Phenelzine*",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Quinidine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Quinine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Trimebutine&bull;,&Delta;",
"          </td>",
"         </tr>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Diminish the neuromuscular effect of NMBAs",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1_start\">",
"           Acetylcholinesterase inhibitors&bull;",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Donepezil",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Galantamine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Neostigmine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Physostigmine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Pyridostigmine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Rivastigmine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Tacrine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1_start\">",
"           Loop diuretics (high doses)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Bumetanide",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Ethacrynic acid",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Furosemide",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Torsemide",
"          </td>",
"         </tr>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    For more details, see specific drug information topic or Lexi-Interact (available to online readers from the main search page).",
"    <div class=\"footnotes\">",
"     * Succinyl choline only.",
"     <br>",
"      &bull; Nondepolarizing NBMAs only.",
"      <br>",
"       &Delta; Not available in United States.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_15_39165=[""].join("\n");
var outline_f38_15_39165=null;
var title_f38_15_39166="Acute insulin response";
var content_f38_15_39166=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F54816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F54816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Relative acute insulin response to IV glucose",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 341px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Brunzell JD, Robertson RP, Lerner RL, et al. Relationships between fasting plasma glucose and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 1976; 42:222. file://jcem.endojournals.org. Copyright &copy; 1976 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_15_39166=[""].join("\n");
var outline_f38_15_39166=null;
var title_f38_15_39167="Esophageal acid-induced bronchoconstriction";
var content_f38_15_39167=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 598px\">",
"   <div class=\"ttl\">",
"    Mechanisms of esophageal acid-induced bronchoconstriction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 578px; height: 316px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_15_39167=[""].join("\n");
var outline_f38_15_39167=null;
    